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Behavioural and psychological symptoms of dementia (BPSD)
include affective symptoms, psychotic symptoms, non-aggressive
agitation, irritability, wandering, elation and sleep problems.1
They have a high prevalence in dementia and nearly all people
with dementia have at least one of these symptoms during the
course of the disease.2 Such symptoms have negative effects on
the quality of life of both patients and caregivers and are
associated with increased costs of care.3,4 Better treatment and
management of the symptoms are important, particularly as there
is no effective treatment to alter the course of the underlying
cognitive and functional decline. In order to design and conduct
clinical trials for the treatment of BPSD, more information about
the pattern of these symptoms in the different stages of dementia
is needed to identify the best stage to intervene. In addition,
insights into the extent to which BPSD occur over the course of
dementia will help patients and care providers to plan for the
future. Cross-sectional studies have shown that BPSD can occur
at any time during the development of dementia. Their prevalence
may increase from mild to severe dementia, whereas other studies
suggest a non-linear course with the highest prevalence seen in the
intermediate stages of disease.5,6 Symptoms may persist or be
episodic over time, and this may differ between symptoms.
Evidence from longitudinal studies is limited and has not been
brought together systematically. Two reviews on the course of
BPSD specifically in care-home residents have been published
recently.7,8 They included a small number of studies (28 and 18)
and concluded that the course of BPSD varied considerably
between studies and between individual symptoms.
Our aim was to determine the longitudinal course of BPSD in
individuals with dementia or in cohorts studied for dementia
onset. We also investigated the persistence and incidence of
symptoms and how persistence of BPSD over time relates to
cognitive function. This review builds on five previous reviews
by some of the same authors.9–13
Method
Studies were eligible for inclusion if they reported the persistence,
incidence or association with cognitive function of one or more
BPSD in older adults (i.e. majority of participants aged at least
65 years) with dementia or cognitive impairment, and measured
symptoms at three or more time points. Observational studies
or intervention studies where there was a control group were
included. The symptoms included were apathy, depressive
symptoms, anxiety, irritability or aggression, non-aggressive
agitation, hallucination, delusion, misidentification, sleep
problems, wandering and elation. No language restriction was
applied. Studies with inadequate descriptions of the sampling of
the population or measurement of BPSD were excluded. The
review protocol was not registered.
Search method
Electronic searches of PubMed, EMBASE, Cinahl and PsycINFO
databases were undertaken to identify potentially relevant articles
published before March 2013. Search terms included text and
MeSH terms for BPSD, dementia and longitudinal study (see
online Fig. DS1). Two authors (R.v.d.L. and B.S.) independently
searched titles and abstracts for potentially relevant articles.
Following this, full text selection was completed by two authors:
R.v.d.L. and A.M.P. (or B.S.). References of included studies were
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Background
More information about the pattern of behavioural and
psychological symptoms of dementia (BPSD) in the course of
dementia is needed to inform patients and clinicians and to
design future interventions.
Aims
To determine the persistence and incidence of BPSD and
their relation to cognitive function, in individuals with
dementia or in cohorts investigated for dementia onset.
Method
A systematic literature review analysed the baseline
prevalence, persistence and incidence of 11 symptoms. The
review was conducted according to established guidelines
with the exception that we could not exclude the possibilities
of bias in the studies examined.
Results
The 59 included studies showed considerable heterogeneity
in their objectives and methods. The symptoms hyperactivity
and apathy showed high persistence and incidence;
depression and anxiety low or moderate persistence and
moderate incidence; and psychotic symptoms low
persistence with moderate or low incidence.
Conclusions
Despite heterogeneity across studies in terms of setting,
focus and length of follow-up, there were clinically
relevant differences in the longitudinal courses of different
BPSD. Apathy was the only symptom with high baseline
prevalence, persistence and incidence during the course
of dementia.
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Review article
searched backwards and forwards, using the literature database
Scopus.
Data synthesis
Data were extracted independently and in duplicate (R.v.d.L.
and B.S. or E.E.). Details extracted from each paper included
setting, participant recruitment method, number of participants,
follow-up time, BPSD and their measurement, number of BPSD
measurements, population age (mean and range), baseline Mini-
Mental State Examination (MMSE) score,14 baseline BPSD
prevalence, statistical methods used, covariates taken into account
and findings on the persistence, incidence and association of
BPSD with cognitive function. Risk of bias was not formally
assessed in a quality assessment. Findings were divided by
dementia severity and BPSD. Dementia severity was defined using
MMSE categories based on clinical practice guidelines from
the National Institute for Health and Care Excellence (NICE):
mild dementia (MMSE score 21–26), moderate dementia (MMSE
15–20), moderately severe dementia (MMSE 10–14) and severe
dementia (MMSE <10).15 When no MMSE score was reported,
equivalent cut-off scores from the Cambridge Cognitive
Examination (CAMCOG), modified MMSE, Clinical Dementia
Rating (CDR) scale and the Alzheimer’s Disease Assessment Scale
(ADAS) were used.16–22 By use of results from factor analyses and
cluster analysis reported in the literature,10 symptoms were
grouped into affective symptoms (comprising depression, anxiety
and apathy), psychosis (comprising delusions and hallucinations),
hyperactivity (comprising irritability, agitation and wandering),
elation and sleep problems.
Where possible the persistence of symptoms was reported as
the percentage of people with a certain symptom at baseline
who also had the symptom at the next measurement or for whom
the symptom persisted during the entire follow-up period.
Incidence was reported as the percentage of people without
symptoms at baseline who had developed new symptoms at the
next measurement or during the entire follow-up period. Results
from a multistate model were reported when available. Studies
investigating the association between BPSD and cognitive function
were summarised by reporting the analysis methods (e.g. Cox
proportional hazards model, latent class linear mixed model or
logistic regression model), covariates taken into account, BPSD
score and results, including hazard ratios, b coefficients and F
or P values.
Baseline BPSD prevalence, persistence, incidence and
association with cognitive impairment were compared for each
of the symptoms in the studies that included several BPSD.
Prevalence, persistence and incidence were summarised as ‘low’
if the majority of studies found that the results were lower than
that of most of the other symptoms included, ‘high’ if the majority
found that results were higher than for most of the other
symptoms and ‘moderate’ if the results were intermediate or
mixed. The range of the results was reported for each symptom.
Results
Owing to considerable heterogeneity in study objectives and
methods, inclusion criteria were revised post hoc. The following
exclusion criteria were added: a follow-up period of less than 3
months; reporting only the prevalence at different time points;
symptom measurement through retrospective caregiver report
(retrospective studies using medical records were included); and
measuring pure major depression or clinical depression only.
Studies reporting on minor depression or depressive symptoms
only or depression as part of BPSD were included (as discussed
in two previous publications).9,11 From 5923 identified articles
48 were selected for inclusion after the abstract and full-text
selection stages. Cross-referencing resulted in an additional 11
studies. In total 59 studies were included.
Study design
Characteristics of the studies included are shown in Table 1 and
online Table DS1. The majority of studies recruited participants
from psychiatric services including memory and dementia clinics
(31 studies out of 59). Participants in these studies typically had
moderate dementia (16 studies) and a younger mean age (in 20
studies participants had a mean age below 75 years). Other studies
recruited participants from the population (8 studies), primary
care (7 studies) or institutional care (8 studies), or recruited
volunteers from other settings (4 studies). One study retrospectively
reviewed medical records. The 8 studies that reported on care-home
residents mostly included older participants (mean age 75 years
or over) with moderately severe or severe dementia. Studies
recruiting participants without dementia (10 studies) were found
for depression only and most of these recruited from the general
population (6 studies). Overall, most studies were from the USA
or Canada (27 studies) and Europe (29 studies). Follow-up times
ranged from 3 months to 14 years: 8 studies had a follow-up
period of 1 year or less, 24 studies a follow-up period of 1–5 years
and 26 had a follow-up period of 5 years or more.
Symptoms
Included symptoms are shown in Table 1 and their baseline
prevalence is summarised in Fig. 1. Full details of each symptom,
its definition, the instrument used for its measurement and the
baseline prevalence can be found in online Table DS2. Affective
symptoms were the most frequently studied (37 studies), with
24 studies reporting on depression only. Anxiety was studied in
11 studies, apathy in 4, and 2 studies reported on a factor of
affective symptoms. Psychotic symptoms were studied in 26
studies (delusions in 20, hallucinations in 21, misidentifications
in 1, psychosis symptoms combined in 5). Hyperactivity
symptoms, including irritability (16 studies), non-aggressive
agitation (often including pacing or wandering) (16 studies),
wandering (4 studies) or a factor of hyperactivity symptoms (6
studies), were studied in 30 studies. Elation was measured in only
5 studies and sleep problems in 9. Many different instruments
exist to measure and define BPSD,12 and 28 different instruments
were used across the included studies. The Neuropsychiatric
Inventory (NPI) was used in 8 studies.23 Five studies used the total
score of a BPSD instrument, rather than presenting individual
symptom profiles.
Prevalence
The baseline prevalence varied widely across the studies (see Fig.
1). Generally, higher baseline prevalence was reported by studies
that included a population with moderate or moderately severe
dementia than by studies that included those with severe dementia
only. A higher prevalence of symptoms was also seen in studies
that recruited participants from psychiatric settings rather than from
the population or institutional care settings (e.g. for depression:
psychiatric settings 20–57%, institutional care 8–20%, population
22%). Studies with a younger mean age typically showed a higher
symptom prevalence (e.g. for delusion: 575 years 24–40%, 75+
years 9–22%). There may also be differences by BPSD instrument.
For example, studies that measured symptoms using the
BEHAVE-AD typically showed a higher prevalence than studies
using the NPI.
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Course of symptoms of dementia
Symptom persistence and remission
The persistence and stability of symptoms or the change in
symptom scores over time were considered for each of the
five symptom domains separately. Figure 2 summarises the
results of studies investigating the persistence of depression,
hallucination and irritability (see online Fig. DS2 for the
persistence of all symptoms). Detailed findings are available in
online Table DS3
Depression, anxiety and apathy
A large variation in persistence of affective symptoms was seen,
with great intra-individual variability.24,25 Aalten et al reported a
relatively low persistence of depression, anxiety and apathy,26
whereas Haupt et al reported a persistence of depression of up to
59% over a 2-year period.27 Anxiety and apathy may be more
persistent over time than depressive symptoms,26,28,29 although
two studies reported that anxiety was less persistent than
depression.27,30 Wetzels et al (study not included in the figures
because it described only the persistence over each observation)
found that resolution of anxiety was consistently higher than
persistence of symptoms, whereas apathy showed a variable
course.31 Where change was modelled statistically, affective
symptoms were generally found to be stable without significant
change over time.32–34
Delusions, hallucinations and misidentifications
The persistence of psychotic symptoms was mostly below 30%
(5 studies), although one study reported that the 6-month
persistence of delusions was 59% and hallucinations 52%.18
Further, multistate models by Eustace et al showed delusions were
persistent over 12 months in 65%.28 Generally, hallucinations were
less persistent than symptoms of delusion,18,26,28,35 although one
study found similar results for delusions and hallucinations,27
and two studies found hallucinations were more persistent than
delusions.30,31
3
Table 1 Sample characteristics of included studiesa
No
dementia
Mild dementia
(MMSE 21–26)
Moderate dementia
(MMSE 15–20)
Moderately severe
dementia (MMSE 10–14)
Severe dementia
(MMSE 0–9)
Age, years: mean 575 75+ 575 75+ 575 75+ 575 75+ 575 75+
Studies of persistence and/or incidence of symptoms
Population-based 52 . 75 .
Primary care 30 . . . .
89 .
50 . .
36 .
Institutional care 76 . . . 31 . . . . .
64 .
87 . .
Psychiatric services 28 . . . . 34 . 39 . . .
29 . . . .
88 . . .
40 . . .
35 . .
45 .
92 .
46 .
43 .
33 .
32 . . . .
26 . . . . .
70 . . . . .
42 .
51 . . . . .
25 .
27 . . .
44 .
41 .
47 .
Volunteers/other 24 . .
Studies of association with cognitive function
Population-based 52 .
58 .
57 .
54 .
55 .
59 .
Primary care 89 .
50 . .
68 .
Institutional care 72 . 64 .
Psychiatric services 61 . 65 . . 69 .
35 . .
43 .
70 . . . .. 60 .
67 .
63 .
Volunteers/other 53 .
56 .
62 .
MMSE, Mini Mental State Examination; NPI, Neuropsychiatric Inventory.
Key:
. Investigated depression, anxiety and/or apathy.
. Investigated delusion, hallucination and/or misidentification.
. Investigated irritability, agitation and/or wandering.
. Investigated elation.
. Investigated sleep problems.
. NPI total score only.
a. Studies identified by reference number. See online Table DS1 for more details.
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Irritability, agitation and wandering
Hyperactivity symptoms were mostly persistent, with one study
showing that up to 76% of individuals had persistent symptoms
of agitation over 2 years.27 Studies that investigated several
hyperactivity symptoms found that agitation was more persistent
than irritability.18,26,27 A study investigating several symptoms of
irritability found that verbal aggression was the most common
and longest-lasting form of aggressive behaviour, whereas
aggressive resistance and physical aggression were most likely to
persist until death.36 King-Kallimanis et al found that wandering
status was more likely to change from wandering to non-wandering
rather than the reverse and that wandering was a temporary phase
for approximately half of care-home residents who were admitted
as wanderers.37 Several authors analysed the course of hyperactivity
over time using repeated measures analysis or a latent class linear
mixed model. Garre-Olmo et al reported that over a 2-year
period hyperactivity symptoms were mostly low and smoothly
increasing (this pattern was found in two-thirds of participants).32
Cohen-Mansfield et al found that aggressive behaviours increased
over time whereas physically non-aggressive behaviours did not
change significantly.38
Elation
The persistence of elation was investigated in only two studies.
Wetzels et al found in severe dementia that, for each two consecutive
assessments at 0–6 months, 6–12 months, 12–18 months and 18–24
months, symptoms were stable in 39%, 18%, 3% and 3%
respectively.31 Over a total follow-up period of 2 years Aalten et
al found in moderate dementia that symptoms were stable over
a 6-month period in 2%, whereas for none of the participants
did symptoms persist over 12 months, 18 months or 24 months.26
Therefore, these results suggest that elation is not persistent.
Sleep problems
Most studies that investigated sleep problems (4 studies) reported
low persistence,26,29,30 or a fluctuating course.31 In only one study
were sleep symptoms reported to be persistent.28
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Fig. 1 Baseline prevalence of behavioural and psychological symptoms; see online Table DS2 for more details. Numbers are the reference
numbers of the included studies. ‘Excluded’ indicates that the study excluded participants with a particular symptom at baseline (i.e. the
prevalence was 0%). Twenty-six studies that did not report baseline prevalence or reported on a population already included in the figure
are omitted. Dep, depression; Anx, anxiety; Apa, apathy; Del, delusions; Hal, hallucinations; Psy, psychosis; Irr, irritability; Agi, agitation;
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Fig. 2 Persistence of (a) depression, (b) irritability and (c) hallucinations.Squares indicate the reported percentage where the symptom
persisted over the measurement period and the lines indicate 95% confidence intervals. The name of the first author is given next to the
corresponding findings. If the study reported the persistence over several intervals, it is included in the figure more than once. Next to the
name of the author the total follow-up time (in months unless specified) and the number of visits are reported. For example, Aalten et al
measured symptoms at 5 visits over 24 months and reported on the percentage of participants with depression present at any
consecutive period of 6 months (depression present at 2 visits), 12 months (present at 3 visits), 18 months (present at 4 visits) or 24
months (present at 5 visits).
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Incidence and absence of symptoms
Online Table DS4 and Fig. DS3 show the incidence of symptoms
and the percentage of participants who did not have symptoms
during the follow-up period. A summary is shown in Fig. 3.
Depression, anxiety and apathy
Affective symptoms commonly develop in people with dementia.
Over a 1-year period a high or moderate depression incidence of
up to 37% was reported by eight studies,26-28,31,39–42 whereas in
others the onset of depression was low compared with other
symptoms.18 The incidence of apathy has been reported to be
particularly high: 64% over 2 years,26 and 14–27% over a 6-month
period.31
Delusions, hallucinations and misidentifications
In four studies the probability of new-onset hallucinations was
reported to be low,18,27,28,31 whereas in another four incidence
was reported to be moderate or high.26,41,43,44 Other psychotic
symptoms including delusions showed a consistently moderate
incidence (11 studies).18,26,27,39,40,44–49
Irritability, agitation and wandering
All included studies that compared the incidence of hyperactivity
with other symptoms (9 studies) concluded that the incidence of
hyperactivity was high or moderate.18,26–28,31,39,40,50,51 Although
the incidence of agitation might be particularly high,18,27,35
wandering might develop less often.37
Elation
The incidence of elation was investigated by three studies that
used the NPI. Aalten et al reported a cumulative incidence over
a 2-year period in 5%,26 Wetzels et al reported that for each 6
months of observation new symptoms were seen in 3–4%,31 and
Gillette-Guyonnet et al reported that new symptoms developed
during a maximum follow-up of 4 years in 8%.51 These results
suggest the incidence of elation is low.
Sleep problems
The probability of the onset of sleep problems was reported in four
studies. No consistent findings were reported: at each 6-month
period the incidence in one study was 15%,28 and in another
2–8%,31 whereas over a total follow-up of 2 years symptoms
developed in 31%,26 and over 4 years in 11%.51
Association with cognitive function
The results of studies investigating the association between the
course of BPSD and cognitive function (25 studies) are
summarised in online Table DS5.
BPSD and subsequent cognitive function
Eight studies investigated the association between depression and
subsequent cognitive decline or development of dementia in those
without dementia at baseline.52–59 Those with persistent
depression showed significant decline over time in global cognitive
function, memory, processing speed, recall and attention.52,53,58
Some found a slight increase in depression score before dementia
diagnosis compared with those who did not develop dementia,55,59
whereas others did not find a significant change in depression
before dementia diagnosis.56,57 In those with dementia,
associations with progression of cognitive function were found
for psychosis,45,60 hyperactivity,43 and depression.33 Two studies
investigated the link between BPSD and mild cognitive
impairment. In one study persistence of depression was associated
with progression to dementia,61 whereas another reported no
difference in persistence between those who were cognitively stable
and those who progressed to dementia.62
Cognitive function and BPSD development
In individuals with dementia, psychosis, hyperactivity, agitation
and physical aggression were associated with greater cognitive
impairment.26,35,38,63–65 In contrast, Marin et al found no
association in dementia between cognitive impairment and
depression, delusion, agitation and irritability.66 Four studies
found that symptoms increased with cognitive decline in the early
stages of dementia and were most commonly seen in moderate
dementia, followed by a declining or stable course in the final
stages of dementia.35,63,64,67 Cognitive function at onset of
wandering was found to differ by type of wandering behaviour;
for example, results suggested that excessive walking was more
common in mild dementia, whereas in severe dementia getting
lost was more likely.68 No association was found between cognitive
function and depressive symptoms in those with dementia,69,70
whereas in those without dementia and without depression at
baseline, cognitive impairment at baseline was associated with
an increase of depressive symptoms over time.54 In those aged
70 years and over cognitive function was found to be associated
with initial scores for depression and anxiety, but not with
symptom change over time.71 Baseline dementia diagnosis was not
significantly associated with severity of depression at follow-up.72
Comparison of symptoms
We summarised the studies investigating several BPSD to compare
baseline prevalence, stability, incidence and association with
cognitive function for each of the symptoms (Table 2). Some
symptoms were studied more often than others, and evidence is
lacking for infrequently studied symptoms such as wandering
(included in only one study investigating several BPSD),30 and
apathy and elation (included in only four studies).26,31,32,51
Depressive symptoms were most often studied (included in 12 of
the 13 studies investigating several BPSD).18,26–32,39,40,50,51 Compared
with other symptoms, the results suggest that the persistence and
incidence of depressive symptoms are moderate. Anxiety seems to
be less prevalent and was reported to have a moderate persistence
and incidence.26–31,51 The few studies investigating apathy
suggest a high prevalence, persistence and incidence of
symptoms.26,31,32,51 The prevalence, persistence and incidence of
psychotic symptoms were suggested to be low to moderate, and
may be particularly low for hallucinations.18,26–32,35,39,40,50,51
Symptoms of hyperactivity were most frequently seen and the
majority of studies reported a higher persistence and incidence
compared with other symptoms.18,26–29,31,32,35,39,40,50,51
Discussion
This systematic review confirms that BPSD are common and
relatively persistent in individuals with dementia. The results
suggest there are differences between symptoms: hyperactivity
and apathy showed high persistence and incidence; depression
and anxiety low or moderate persistence and moderate incidence;
and psychotic symptoms low persistence and a moderate or low
incidence. Studies of the association between BPSD and cognitive
function suggest that in those without dementia the presence of
depression is associated with subsequent cognitive decline. In
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Fig. 3 Incidence of (a) depression, (b) irritability and (c) hallucinations. See Fig. 2 for an explanation of the symbols. NR, not reported.
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those with dementia, psychosis, hyperactivity, agitation and physical
aggression were associated with greater cognitive impairment.
Strengths and limitations
Standardised procedures were used for the literature search and
data extraction, including double reading to ensure quality.
However, no established search term for BPSD exists and therefore
relevant studies may have been missed. The reference lists of
included articles and reviews were searched to minimise the
number of missed articles. The review included studies with a
high degree of heterogeneity in study design and population
characteristics, including large differences in the period over
which the persistence and incidence was reported (1 month to
4 years), the total follow-up time (3 months to 14 years), the
instrument and cut-off score used to measure symptoms, the
number of symptoms measured, dementia severity, recruitment
setting and mean age. This made cross-study comparisons difficult
and a meta-analysis was not possible. We were not able to
investigate whether the course of BPSD differs between types of
dementia as only five of the 59 studies reported findings by
dementia type. We adhered to most of the items of the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines (see online Table DS6).73 Although we have
reported on a range of factors that might influence the quality of
the study, risk of bias was not formally assessed in a quality assess-
ment. Our review therefore does not meet items 12, 15, 19 and 22
of the guidelines. Bias in the included studies may have led to an
overestimate of persistence (e.g. participants remained under
medical attention) or to an underestimate of persistence (e.g. gaps
in the follow-up period or attrition through death or care-home
admission). In addition, the review protocol was not registered.
Study differences
Many different instruments exist to measure BPSD,74 and 28
different instruments were used by the studies included in
this review. However, the increasing use of the NPI might
improve comparability of future studies.13 The NPI was used by
eight studies. In these studies the baseline prevalence seemed
lower than that reported by studies using other instruments
(e.g. for irritability, NPI rates were 19–37%, Present Behavioural
Examination (PBE)93 25–89% and BEHAVE-AD94 42–57%). The
total score on the NPI significantly increased over time,26,34,75
and symptoms were mostly shown to be persistent,26,31 stable or
increasing.32,76 The incidence reported by the studies using the
NPI was low or moderate compared with studies using other
instruments.26,31,51
Loss to follow-up is a challenge in longitudinal studies, and
we have reported the number of participants at the end of the
follow-up period for the included studies (online Table DS1).
There was large variation in follow-up completion (24–100%,
although often not reported) and reasons for leaving the study
were often not reported. Persistence of BPSD may be associated
with mortality and with refusal to participate in follow-up
interviews, and differences in follow-up completion may have
influenced the results. Furthermore, we have used study baseline
as a proxy for disease and symptom onset and this may
have affected the findings on the persistence of symptoms.
Symptom course may be influenced by pharmacological or non-
pharmacological interventions. Although there was large variation
in medication use between study populations, in the majority of
studies that included a sensitivity analysis the results were not
altered when taking into account medication use. As we are not
aware of a formal definition of high prevalence, persistence or
incidence, we summarised the findings as ‘low’ if the majority
of studies found that the results were lower than that of most of
the other symptoms included, ‘high’ if the majority found that
results were higher than for most of the other symptoms and
‘moderate’ if the results were intermediate or mixed.
Interpretation of findings
Prevalence
The prevalence of symptoms varied across the studies and
between symptoms. Depression, apathy, irritability, agitation and
wandering showed a high prevalence, whereas the prevalence of
anxiety, hallucination and elation was low. Some studies consistently
reported a relatively low prevalence of symptoms,18,26,31,66 whereas
others consistently reported a relatively high prevalence.27,28,32
Differences might be due to variability in study design, population
characteristics or measurement of symptoms. Indeed, a higher
prevalence of symptoms was generally seen in studies that
recruited participants with less severe dementia, in studies that
recruited from psychiatric settings rather than from the
population or institutional care settings, and in studies with a
younger mean age. There may also be differences due to the BPSD
instrument used.
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Table 2 Results of 13 studies reporting at least two behavioural and psychotic symptoms of dementia
Symptoms
Number
of studies
Baseline prevalence (%)
11 studies
Persistence (%)a
10 studies
Incidence (%)b
9 studies
Affective 12 High Moderate Moderate
Depression 12 High (8–57%) Moderate (16–70) Moderate (10–73)
Anxiety 8 High (17–52%) Moderate (17–52) Moderate (12–38)
Apathy 4 High (19–51) High (20–55) High (27–64)
Psychosis 13 Low Moderate Moderate
Delusions 10 Moderate (9–40) Low (0–82) Moderate (5–84)
Hallucinations 11 Low (0–18) Low (0–52) Low (4–45)
Hyperactivity 12 High High High
Irritability 9 High (6–57) Moderate (12–80) High (10–69)
Agitation 7 High (18–87) Moderate (21–77) High (19–80)
Wandering 1 NR High (60) NR
Elation 4 Low (3–9) Low (2–39) Low (4–5)
Sleep problems 7 Moderate (6–11) Low (10–57) Low (8–31)
NR, not reported.
a. Percentage of symptoms persistent over 3 months or more.
b. Percentage incidence over 3 months or more.
Course of symptoms of dementia
Persistence
Large differences in persistence were seen across symptom
groups and individual symptoms. Affective symptoms (including
depression, anxiety and apathy) generally showed a moderate
persistence, although a limited number of studies reported
persistence of apathy to be high and in one study it was reported
to be higher than for any other symptom.26 Persistence of
psychosis was low to moderate. In contrast, hyperactivity
symptoms showed a high persistence. This is an issue of concern
as these symptoms are among those most problematic for
caregivers.77,78 A low persistence was seen for elation and sleep
problems. Differences in symptom persistence may reflect the
nature of the symptom or might be explained by factors such as
more widely available treatment options for depression and
anxiety. Differences in dementia severity and baseline BPSD
prevalence are likely to have affected results on persistence of
symptoms. Persistence may be higher in those with more severe
cognitive impairment at baseline,32,35,38,46 and a higher BPSD
prevalence.32,39 However, associations between study characteristics
and results could not be tested because of the large degree of
heterogeneity in study design and population characteristics.
Incidence
The results suggest that affective symptoms and hyperactivity
symptoms commonly develop in people with dementia. Large
differences in reported incidence were seen between studies. For
example, the reported incidence of depression ranged from 12%
over a mean follow-up period of 52 months,44 to 73% over a
maximum follow-up period of 9.3 years.40 Differences in study
design and differences in baseline prevalence of symptoms are
likely to have influenced the results. For example, the reported
incidence might be higher in studies that reported a high baseline
prevalence,27 compared with studies with a low baseline
prevalence,18,28 although no formal analysis of the association
between study characteristics and incidence was possible.
Role of cognition
The presence of depression before the onset of dementia was
associated with subsequent cognitive decline.52,53,58 In dementia,
psychosis, hyperactivity, agitation and physical aggression were
associated with greater cognitive impairment.35,38,63–65,70 Symptoms
may be most common in moderate dementia, followed by a
declining or stable course in the final stages of dementia.35,63,64
However, heterogeneity in the pattern of findings across studies
investigating the associations between BPSD and cognitive
function prevented us from drawing more specific conclusions.
The heterogeneity of results does, however, suggest that BPSD
do not solely arise secondary to cognitive impairment.
Study implications
The results from this systematic review suggest that some
symptoms such as hyperactivity are more persistent than others
such as elation and sleep problems. In particular apathy,
irritability, agitation and wandering showed a high persistence.
These symptoms should be targeted in clinical trials to improve
management and intervention. Clinical trials typically follow
participants with more severe dementia over a short period.79,80
However, results presented here show that symptoms may persist
over long periods until death,18,30,42 and may be most common in
moderate dementia.35,63,64,67 Clinical trials focusing on the earlier
stages of dementia with a long follow-up time might therefore be
particularly informative. Results could also inform patients and
care providers about which symptoms are most likely to recur,
so that measures can be put in place to reduce their impact.
Recommendations for monitoring of patients and symptom
management interventions are outlined in guidance by the
Alzheimer’s Society.81
Future research
The heterogeneity in methods and results emphasises the
importance of clearly reporting the study design, population
characteristics and symptom definitions. Table 1 shows that
studies typically included younger populations with moderate
dementia, whereas studies recruiting those with mild or moderate
dementia from the population or from primary care settings were
lacking. As BPSD patterns may differ in these populations, they
should be the focus of future studies. In addition, all included
studies were conducted in high-income countries and the findings
may therefore not be applicable outside these settings. Apathy was
infrequently studied, and as the limited results suggest that it may
have a high persistence and incidence, we recommend that this
symptom should be the focus of future studies on symptom
course.
These methodological issues reiterate the findings from several
of our previous reviews. A review of reviews showed a focus
on individual symptoms (particularly depression), raised the
question how best to define and measure BPSD within and across
populations, and recommended reporting more clearly the
characteristics of the population, the inclusion and exclusion
criteria and how BPSD were defined and measured.9 Two reviews
concluded that there were many instruments to measure
BPSD,12,13 of which the NPI – a short, informant-based question-
naire measuring ten symptoms – has been cited most frequently
and should form the core of any battery, although researchers
choosing instruments should carefully address any gaps in its
content with regard to their research question. In a guest editorial
we discussed that the populations used in studies of depression
and BPSD are often not quite comparable and that the results
therefore cannot be readily extrapolated.11 Finally, we showed that
studies investigating symptom groups show relatively consistent
results, although there remains a large amount of individual
variability.10
Studying covariates that may be associated with higher
persistence of BPSD, including impairment in activities of daily
living,27,32,64 as well as medication use,38,46 could improve
understanding of potential mechanisms involved in the presence
and persistence of BPSD. Environmental factors such as
overstimulation and a person’s surroundings, as well as physical
factors such as pain and dehydration, are recognised as important
triggers for BPSD.5,82–85 These factors are often difficult to capture
and have not been investigated in the studies included here.
Clinical implications
Our findings underscore the existing evidence that BPSD are
common in dementia and that they are also relatively persistent.
Different symptoms have a variable course over time: for example,
psychotic symptoms have relatively low persistence – that is, they
may resolve during the course of the dementia. In contrast, apathy
emerged as the only individual symptom with high baseline
prevalence, high persistence and also a high incidence during
the course of the dementia. Thus, increased interest in apathy as
a possible early sign of dementia, as a marker for underlying brain
changes and as a sign of progression of dementia seems entirely
warranted.86 Although hyperactivity as a whole also had high
baseline prevalence, high persistence and high incidence over time,
the various symptoms subsumed under hyperactivity mean that it
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is not a unitary phenomenon. These findings are relevant to
clinicians as they indicate which symptoms may be expected to
persist or to occur anew, and therefore give a better understanding
of the natural history of BPSD which, in turn, can influence
approaches to management and treatment.
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Fig DS1 Overview of the search terms 
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Table DS1 Characteristics of included studies 
            
 
       Author Year Setting  Details setting Reports Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
n at 
baseline 
n with 
complete 
follow-up 
Baseline 
MMSE 
Dementia 
type 
Age 
minimum  
Age mean BPSD 
instrument 
Interview BPSD 
Mild dementia (MMSE 21-26)                            
22 Eustace 2002 DC National referral centre for 
people with memory 
disorders, Ireland 
Per, Inc 24 3 12 216 52 21.6 AD NR (SD 7.8) 73.3 BEHAVE-AD INF Dep, Anx, Irr, 
Agi/Wan, Hal, Del, 
Sle  
16 Clare 2012 DC Memory clinics in North 
Wales, UK 
Per 20 3 8-12 101 51 24.2 (18+) AD, VD, 
mixed 
  78.7 HADS; NPI INF Dep, Anx, Total 
score 
52 Tschanz 2011 PB  Cache County Study, USA Per Mean 3.8 
yrs., max 
12.9 yrs. 
Mean 1.9 NR 328 33% 21.9 AD   85.9 NPI INF Total score 
Moderate dementia (MMSE 15-20)                          
39 Levy 1996 NR NR (clinical trial), USA Per, Inc 12 5 3 215 181 20 AD 51 70.8 ADAS INF Dep, Agi/Wan, Psy 
8 Berger 2005 DC Outpatient Memory Clinic 
of university, Germany 
Per, Inc 24 5 3-6 45 18 20 NR 48 70.6 BEHAVE-AD CLIN? Dep, Anx, Hal, Del, 
Irr, Agi/Wan, Sle 
29 Holtzer1b 2005 DC 3 sites in USA and 2 sites in 
Europe (Paris and Greece) 
(1b) 
Cog max: 14 
yrs. 
max: 28 6 536 130 (5 
yrs.) 
NR AD   74 CUSPAD INF Dep 
51 Scarmeas1b 2007 DC See 1b Per, Cog max:14 yrs. max:25 6 497 NR 16+ AD 49 74 CUSPAD NR Agi, Irr, Wan 
50 Scarmeas1b 2002 DC See 1b Inc max: 9.3 
yrs. (mean 
5.5 yrs.) 
NR 6 87 NR NR AD   70.7 CUSPAD INF Dep, Behavioural 
(Agi, Wan, Irr) , Hal, 
Del 
20 Devanand1a 1997 DC 3 medical centres, USA (1a) Per, Inc 5 yrs. 
(mean 3 
yrs.) 
7 6 235 137 NR AD 82.1% 65+ 73.1 CUSPAD INF Dep, Irr, Agi/Wan, 
Hal,Del, Mis 
28 Holtzer1a 2003 DC See 1a Per, Inc, 
Cog 
5 yrs. 11 6 236 102 NR AD   72.7 CUSPAD INF Irr, Agi/Wan, Hal, 
Del 
24 Garre-
Olmo 
2010 DC Memory Clinic of hospital, 
Spain 
Per 24 5 6 491 253 NR AD 48 75.2 NPI INF Apa, Dep, Anx, Irr, 
Agi/Wan, Hal, Del,  
Sle, Eat, Dis 
1 Aalten2 2005 DC Outpatients of Memory 
Clinic of University 
Hospital, or psychiatry 
clinic, The Netherlands (2) 
Per, Inc 24 5 6 199 99 18.1 AD, VD, LBD, 
mixed 
53 76.4 NPI INF Apa, Dep, Anx, Irr, 
Agi/Wan, Hal, Del, 
Sle, Ela, Eat, Dis 
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2 Aalten2 2005 DC See 2 Per, 
Cog 
24 5 6 199 99 18.1 AD, VD, LBD, 
mixed 
53 76.4 NPI INF Apa, Dep, Anx, Irr, 
Agi/Wan, Del, Hal, 
Sle, Ela, Eat, Dis 
25 Gillette-
Guyonnet 
2011 DC 16 memory clinics in France, 
community dwelling 
Inc max 48 mean 5.1 6 686 207 20.0 (10-
26/30) 
AD   77.9 NPI INF Apa, Dep, Anx, Irr, 
Agi/Wan, Sle, Hal, 
Del, Ela 
59 Zahodne 2013 DC Outpatient clinics and 
clinical research centres at 3 
sites in USA and 1 in France 
Per, 
Cog 
5.5 yrs. mean 10.1 6 509 167 NR AD   74.2 CUSPAD INF Dep 
49 Rosen  1991 DC Ambulatory care setting, 
living in the community, USA 
Per, Inc 6 yrs. 7 1 yr. 32 7 at least 
3 assess-
ments 
15.5 AD NR (SD 7.9) 70.3 DSMIII INF + PAR Hal, Del 
48 Paulsen 2000 DC Alzheimer’s Disease 
Research Centre of 
University, USA 
Inc Until 
death, 
reported 
for 5 yrs. 
5 1 yr. 329 NR NR AD NR (SD 6.4-
7.7.7) 
72.6 DIS  for the 
DSMIII 
INF Hal, Del 
56 Wilkosz 2006 DC Alzheimer disease research 
centre of University, USA 
Inc mean: 25.8  NR 1 yr. NR 288 at 
least 1 
follow-up 
20.09 AD or MCI 38 74.3 CERAD INF Hal, Del 
Moderately severe dementia (MMSE 10-14)                          
19 Deudon 2009 CH Nursing homes in 2 regions, 
France 
Per 3 3 1 or 2 132 114 12.1 Not reported NR (SD 6.7) 86 CMAI, NPI 
and 
Observation 
Scale 
INF Agi, Irr, Psy, 
Hyperactivity (Wan, 
Ela, Irr) 
23 Fauth 2006 NR Community outreach and in-
home respite programs 
(control group only), USA 
Per 3 4 1 85 NR 13.3 Not reported NR (SD 8.8) 79.6 Daily record 
of behaviour 
(DRB) 
OBS Dep, Agi/Wan, Irr,  
Sle, Total score 
6 Ballard3 1996 CLIN/ 
DC 
Old-age psychiatry services 
and a memory clinic, UK (3) 
Per, Inc 12 12 1 124 89 NR AD, VD, DLB NR 79.7 Cornell scale INF + PAR Dep 
5 Ballard3 1997 CLIN/ 
DC 
See 3 Per, Inc 12 12 1 125 87 NR AD, VD, DLB NR 79.9 Burn's 
symptom 
checklist 
NR Psy 
35 Keene5 1999 CLIN Recruited through local 
general practitioners, 
community psychiatric 
nurses and consultant old-
age psychiatrists, UK (5) 
Per max: 10 
yrs. 
30 4 99 NR (n=88 
followed 
until 
death) 
NR AD, VD   NR PBE INF Irr 
31 Hope5  2001 CLIN See 5 Cog max: 9 yrs. mean:10.5 4 86 NR (n=77 
until 
death of 
which 75 
>1yr) 
NR AD, VD   NR PBE    INF Wan 
44 McShane5 1995 CLIN See 5 Per, 
Cog 
max: 5 yrs. 
(until 
death) 
NR 4 98 41 (who 
had died) 
13 AD   NR PBE INF Hal 
30 Hope5  1999 CLIN  See 5 Per max: 9 yrs. NR 4 100 48 (at 
least 1 
yr.) 
14 AD, VD, 
mixed, other 
60 78 PBE and Past 
behavioural 
history 
INF Dep, Anx, Irr, Hal, 
Del, Sle, Wan, Eat 
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interview 
45 McShane5 1998 CLIN See 5 Inc, 
Cog 
max: 4 yrs. 
(until 
death) 
NR 4 86 80 (>4yrs 
or until 
death) 
15 AD, VD, DLB, 
Other 
  77 PBE INF Dep, Anx, Irr, Hal, Del 
4 Asada 1999 DC + 
VOL 
Outpatients at clinic, 
voluntary patients whose 
caregivers were members of 
a self-help network and 
patients identified by formal 
service providers, Japan 
Cog 5 yrs. 6 12 103 31 NR AD NR (SD 8.7) 79.4 Troublesome 
behaviour 
scale (TBS) 
INF Agi/Irr factor, Wan 
factor 
47 Neundorfer 2001 DC University hospitals, 
Alzheimer disease research 
centre, USA 
Per max:5 yrs. max:10 12 353 NR NR AD, other 50 73 CERAD INF Dep 
43 McCarty 2000 DC Memory Disorders Clinic at 
University, USA 
Cog 24 3 12 150 61 13.52 AD 56 74.2 Memory and 
Behaviour 
Problem 
Checklist-
Revised 
INF Apa factor; 
Dep/Anx/Agi/Wan/Irr 
factor 
26 Haupt4 1996 DC Outpatient Clinic of 
University, Germany (4) 
Cog 24 3 12 90 61 NR AD 57 74.3 BEHAVE-AD INF + PAR Hal, Del 
27 Haupt4 2000 DC See 4 Per, Inc 24 3 12 90 60 13.5 AD 57 73.4 BEHAVE-AD INF + PAR Dep, Anx, Irr, 
Agi/Wan, Hal, Del 
14 Chang 2004 DC Memory clinic for veterans, 
Taiwan 
Inc mean: 51.9 NR NR 56 NR (>1 
visit) 
NR AD NR (SD 8.8) 74.2 SCID DSM 
IIIR 
INF + PAR Dep, Hal, Del 
Severe dementia (MMSE 0-9)                           
55 Wetzels 2010 CH Dementia special care units 
from nursing homes, The 
Netherlands 
Per, Inc 24 5 6 290 117 7.6 AD, VD NR (SD 7.4) 81.7 NPI nursing 
home 
version 
INF Apa, Dep, Anx, Irr, 
Agi/Wan, Hal, Del, 
Sle,  Ela,  Eat, Dis 
12 Burgio 2007 CH Nursing homes, USA Per, 
Cog 
18 4 6 78 55 8 AD, VD, 
mixed, 
uncertain 
59.8 82.2 Modified 
NHBPS and 
observation 
INF + OBS Irr 
 
18 de Rooij 2012 CH 5 long-term care settings 
in The Netherlands and 
Belgium 
Per 12 3 6 179 126 S-MMSE 6.1 Not 
reported 
NR 85.9 QUALIDEM INF Dep, Agi 
Normal cognitive function (MMSE 27+, no dementia) 
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37 Kohler  2010 POP Collaborative network of 
family practices, the 
Netherlands 
Per, 
Inc, 
Cog 
6 3 3 598 412 27.7 
(MMSE<24 
excluded) 
Not 
reported 
60 69.4 Symptom 
Checklist 
NR Dep 
7 Becker  2009 POP Non-institutionalised 
individuals from the Part 
A Medicare list, USA 
Cog max: 9 
yrs. 
9 12 441 288 (at 
least 3 
measures) 
NR 
(cognitively 
normal at 
baseline) 
AD 70 77.5 CES-D NR Dep   
53 Vinkers 2004 POP Population-based study 
of all 85 year old 
inhabitants of city, The 
Netherlands 
Cog 4 yrs. 5 12 500 298 27 
(MMSE<19 
excluded) 
Not 
reported 
All aged 85 85 GDS15 NR Dep 
3 Amieva 2008 POP Population-based sample 
of community dwelling 
individuals, France 
Cog max: 14 
yrs. 
7 12-36 350 who 
developed 
AD and 350 
control 
25 AD 
and 24 
control 
NR 
Dementia 
free at 
baseline, 
those who 
developed 
dementia 
during 
follow-up 
compared to 
control. 
AD 65 86.2 CES-D NR Dep 
58 Wilson  2010 POP Census of a 
geographically defined 
region of city, USA 
Cog max: 8-9 
yrs. 
mean:3.6/4.0 36 357+340 NR (100% 
/ 90% 
"longitu-
dinal 
data") 
Initially 
dementia 
free; 20.4 at 
dementia 
diagnosis 
AD 65 82.5 CES-D (10-
item) and 
Hamilton 
Depression 
Rating Scale 
(0-35) 
INF + 
PAR 
Dep 
9 Bielak 2011 POP Electoral role Australian 
citizens, Australia 
Cog max: 15 
yrs. 
(mean: 
6.0 yrs.)  
5 2-6yrs 1,206 NR NR (without 
dementia) 
Not 
reported 
70 78.16 CES-D PAR Dep 
32 Houde 2008 DC Memory Clinic of 
university General 
Hospital, Canada 
Cog max: 10 
(mean: 
4.3 yrs.) 
max:11 1 60 NR 27.2 (MCI) MCI, AD 55 74.5 GDS NR Dep 
21 Dotson  2008 VOL Community dwelling 
generally healthy group 
of volunteers, USA 
Cog max 26 
yrs. 
9mean: 
4.4 yrs.) 
NR 24 1,586 NR 28.65 
(without 
dementia) 
Not 
reported 
50 65.4 CES-D PAR Dep 
41 Mackin  2011 VOL Alzheimer’s Disease 
Neuroimaging Initiative, 
USA and Canada 
Per, 
Cog 
3 yrs. 4 12 405 227 27.2 (MCI) MCI NR 74.9 GDS NR Dep 
57 Wilson  2008 OTHER Older Catholic nuns, 
priests and brothers, USA 
Cog max: 13 
yrs. 
mean:7.8 24 917 23 (13yrs; 
5+yrs: 
630) 
27.4 No 
dementia at 
baseline, 
some 
developed 
MCI, AD 65 74.8 CES-D PAR Dep 
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AD during 
follow-up 
Comparing cognitive groups                            
33 Janzing 2000 CH 6 homes for the elderly 
in the specified region, 
The Netherlands 
Cog 12 3 6 201 121 (49 
dem) 
18.2 
(moderate 
dementia) 
and 26.7 
(normal) 
Not 
reported 
NR (SD 5.3; 
6.5) 
86.6 
(dem); 
82.6 
(normal) 
GMS 
AGECAT 
PAR? Dep 
10 Blansi 2005 DC Memory Clinic of 
University Hospital and 
control sample, 
Switzerland 
Cog max: 3-4 
yrs. 
3-4 12 662 (217 
dem) 
36 (dem 
4+ visits) 
26.1 (AD, 
24+); 28.8 
(control) 
AD 50 73.4 NOSGER INF Dep, Disturbing 
behaviour 
40 Li  2001 DC + VOL Cognitively impaired 
outpatients and 
cognitively normal 
volunteers, USA (76% 
treated with 
antidepressant 
medication) 
Per, 
Inc 
max 7.8 
yrs. 
(mean 
3.5 yrs.) 
NR 3-12 294 (129 
dem) 
239 (3+ 
visits, 93 
dem) 
17 
(moderate 
dementia); 
29 (normal); 
26.1 (MCI) 
MCI, AD, 
VAD 
50 76.5 HDRS PAR Dep 
11 Bunce 2012 PB 
(community) 
Aged 70 and over living 
in the community in 
Canberra or nearby, 
Australia 
Cog max: 12 
yrs. 
max 4 4yrs 837-870 95 NR Not 
reported 
70 76.6 Goldberg 
Depression 
and Anxiety 
Scales 
PAR Dep, Anx 
 Dementia severity not reported  
36 King-
Kalli-
manis  
2010 CH Veterans Administration 
nursing homes, USA 
Per, 
Inc 
4 yrs. 
(mean 
390/297 
days) 
mean:4 3 6,673 NR NR Not 
reported 
24 72.5 Minimum 
dataset 
NR Wan 
54 Volicer 2012 CH 8 nursing homes, The 
Netherlands 
(retrospective Minimum 
Dataset analysis) 
Per 15 4 3 1101 1101 NR AD, other, 
mixed 
65 84.2 Minimum 
dataset 
NR Agi/Wan 
46; 38 Morgan; 
Kunik 
2012 DC Veterans administration 
outpatient data files, 
flyers, radio and print 
advertisements and the 
primary care and 
geriatrics clinic (94% 
male), USA 
Inc 24 7 4 171 NR NR Not 
reported 
60 75.8 CMAI INF Irr 
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17 Cohen-
Mans- 
field 
1998 CH? Community dwelling, 
senior day care centres in 
Maryland, USA 
Per, Cog 24 5 6 200 104 NR AD, VD, PD, 
unknown, 
no 
diagnosis 
60 79.2 CMAI-C INF Irr, Agi 
15 Chen 1991 DC Patients presenting for 
evaluation of dementia in 
a clinical practice, USA 
Inc mean 5 yrs. 2 or 
more 
6 72 NR (29 
followed 
until 
death) 
NR AD At onset 
AD: 64.1, 
mean 
duration at 
baseline: 
3.0 years 
NR DSMIII-R  INF + 
PAR 
Psy 
34 Jost  1996 DC Autopsy confirmed AD 
patients enrolled in a 
regional brain bank 
through a university 
geropsychiatry clinic and 
by clinicians and caregivers 
in surrounding 
communities, USA 
Inc Retrospective 
using medical 
records 
  Retrospective Retrospective 100 NR AD NR NR Medical 
record 
review 
  Dep, Anx, Irr, Hal, 
Del, Sle 
42 Marin 1997 DC Alzheimer's disease 
Research Centre, USA 
Cog mean 37.1 mean:6.0 6 201 153 (12+ 
months) 
NR AD 50 86.6 ADAS INF Dep, Irr, Agi, 
Agi/Wan, Hal, 
Del, Total score 
13 Caligiuri  2003 NR NR, USA Inc 24 3 12 54 NR NR AD NR (SD 8.6) 77.1 BEHAVE-
AD 
INF Hal, Del 
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Reference numbers refer to the Online Reference List 
 
Papers from the same study groups: 
1a Predictors study 1: Columbia Medical Centre, John Hopkins 
University School of Medicine, Massachusetts General Hospital, 
USA 
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in 
Europe (Paris and Greece) 
2 Maasbed study  
3 Ballard et al. (Psychiatry services in the West Midlands and a 
memory clinic in Bristol) 
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of 
the Technical University in Munich) 
5 Hope et al. (Oxford) 
 
 
 
 
 
 
Reports on: 
Per=Persistence 
Inc=Incidence 
Cog=Association with cognitive function 
 
Settings  
DC=Dementia or memory clinic 
POP=Population-based 
CH=Care home 
CLIN=Referred by clinicians 
VOL=Volunteers 
NR=Not reported 
 
Data collection 
INF=Informant-based 
PAR=Participant-based 
OBS=Observation 
 
 
 
BPSD= behavioural and psychological symptoms of dementia 
Apa=apathy 
Dep=depression 
Anx=anxiety 
Irr=irritability/aggression 
Agi=agitation 
Hal=hallucination 
Per=persecution 
Mis=misidentification 
Sle=sleep problems 
Wan=wandering 
Ela=elation 
 
AD=Alzheimer’s disease 
VD=Vascular Dementia 
DLB=Dementia with Lewy Bodies 
MCI=Mild Cognitive Impairment 
PD=Parkinson’s Disease 
NR=not reported 
MMSE=Mini Mental State Examination 
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Table DS2 Definition and baseline prevalence of BPSD 
Affective symptoms 
 
  Author Year Instrument  Depression / Anxiety / Apathy   
         Definition Prevalence (%) 
 Mild dementia (MMSE 21-26)      
 22 Eustace 2002 BEHAVE-AD Dep: Tearfulness and other depressed mood (e.g. death 
statements) with or without clear affective or physical 
components Anx: Anxiety about upcoming events, other 
anxieties, fear of being left alone, other phobias 
Dep: 33 Anx: 52 
 16 Clare 2012 HADS; NPI 
total 
Dep: 8 items including a loss of interest, laughing less, being 
less cheerful, being less optimism, and not being hopeful 
about the future Anx: 8 items including about feeling tense, 
worrying, panic attacks, feeling something awful is about to 
happen 
NR 
 Moderate dementia (MMSE 15-20)   
 39 Levy 1996 ADAS Dep: Tearfulness and depression Dep: 23 
 8 Berger 2005 BEHAVE-AD Dep: Tearfulness and other depressed mood (e.g. death 
statements) with or without clear affective or physical 
components Anx: Anxiety about upcoming events, other 
anxieties, fear of being left alone, other phobias 
Dep median 0.5 Anx 
median 0.0 
 29 Holtzer1b 2005 CUSPAD Dep: Depressed mood (sad, depressed, blue, down in the 
dumps), difficulty sleeping and change in appetite 
Dep: 40 
 50 Scarmeas1a 2002 CUSPAD Dep: Depressed mood (sad, depressed, blue, down in the 
dumps), difficulty sleeping and change in appetite 
Dep: 43.7 
 20 Devanand1a 1997 CUSPAD Dep: Depressed mood (sad, depressed, blue, down in the 
dumps), difficulty sleeping and change in appetite 
Dep: 25.1 
 24 Garre-Olmo 2010 NPI-10 Dep: Includes seeming sad or depressed, saying or acting as if 
sad or in low spirits Anx: Includes being very nervous, being 
worried, or frightened, being tense Apa: Loss of interest, more 
difficult to engage, apathetic or indifferent 
Dep: 43.8 Anx: 31.2 Apa: 
51.3 
 1 Aalten2 2005 NPI Dep: Includes seeming sad or depressed, saying or acting as if 
sad or in low spirits Anx: Includes being very nervous, being 
worried, or frightened, being tense Apa: Loss of interest, more 
difficult to engage, apathetic or indifferent 
Dep: 35.2 Anx: 21.1 Apa: 
40.2 
 2 Aalten2 2005 NPI Mood/apathy cluster: depression, apathy, night-time 
behaviour disturbances and eating abnormalities (See Aalten2) 
See Aalten2 
 25 Gillette-
Guyonnet 
2011 NPI Dep: Includes seeming sad or depressed, saying or acting as if 
sad or in low spirits Anx: Includes being very nervous, being 
worried, or frightened, being tense Apa: Loss of interest, more 
difficult to engage, apathetic or indifferent 
Dep: 20.6 Anx: 23.9 Apa: 
43.0 
. 
59 Zahodne 2013 CUSPAD Dep: Depressed mood (sad, depressed, blue, down in the 
dumps), difficulty sleeping and change in appetite 
Mean 0.74 (0-4) 
 Moderately severe dementia (MMSE 10-14)   
 23 Fauth 2006 Daily record 
of 
behaviour 
(DRB) 
Dep: Mood, include crying and being tearful NR 
 6 Ballard3 1996 Cornell 
scale 
Dep: Sadness, sad expression, sad voice, tearfulness, 
lack of reactivity to pleasant events 
Dep: minor 23.6; major 
23.6 
 30 Hope5  1999 PBE and 
Past 
behavioural 
history 
interview 
Dep: Apparent sadness, appearing to be particularly sad, 
miserable or depressed Anx: Anxiety or fearfulness (with 
physical symptoms) 
NR 
 45 McShane5 1998 PBE Dep: Apparent sadness, appearing to be particularly sad, 
miserable or depressed Anx: Anxiety or fearfulness (with 
physical symptoms) 
Dep: 27.9 Anx: 16.3 
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47 Neundorfer 2001 CERAD Dep: Feelings of anxiety, sad appearance, hopelessness, 
crying, feelings of guilt, poor self-esteem and feelings that life 
is not worth living 
NR 
 43 McCarty 2000 Memory 
and 
Behaviour 
Problem 
Checklist-
Revised 
Apathy cluster: forgetting the day, can’t self-start activities, 
unable to keep busy, following people, spends time inactive, 
talking little or none, sad/depressed  
mean 1.34 (0.66) of max 
3.00 
 27 Haupt4 2000 BEHAVE-AD Dep: Tearfulness and other depressed mood (e.g. death 
statements) with or without clear affective or physical 
components Anx: Anxiety about upcoming events, other 
anxieties, fear of being left alone, other phobias 
Dep: 57 Anx: 35 
 14 Chang 2004 SCID DSM 
IIIR 
Dep: SCID diagnosis   
 Severe dementia (MMSE 0-9)     
 55 Wetzels 2010 NPI nursing 
home 
version 
Dep: Includes seeming sad or depressed, saying or acting as if 
sad or in low spirits Anx: Includes being very nervous, being 
worried, or frightened, being tense Apa: Loss of interest, more 
difficult to engage, apathetic or indifferent  
Dep: 8.5 Anx: 17.1 Apa: 
18.8 
 18 de Rooij 2012 QUALIDEM Dep: negative affect NR 
 Normal cognitive function (MMSE 27+, no dementia)   
 37 Kohler  2010 Symptom 
Checklist 
Dep: As in Symptom Checklist Dep: 22 scored high 
 7 Becker  2009 CES-D Dep: Includes depressed affect, positive affect, somatic 
complaint, interpersonal problem 
NR 
 53 Vinkers 2004 GDS15 Dep: Satisfaction with life, dropping activities and interests, 
feeling life is empty, being bored, not being hopeful about 
future, being bothered by thoughts, not being in good spirits, 
being afraid, feeling less happy, feeling helpless, being restless, 
not going out, worrying, memory problems, feeling 
downhearted and blue, feeling worthless, being less excited, 
having less energy, feeling upset, crying, difficulty 
concentrating, not enjoying getting up, avoiding social 
gathering, being less decisive, not having a clear mind 
Dep: Median score: 2, 
score 2 or less: 67% 
 3 Amieva 2008 CES-D Dep:  Includes depressed affect, positive affect, somatic 
complaint, interpersonal problem 
NR 
 58 Wilson  2010 CES-D (10-
item) and 
Hamilton 
Depression 
Rating Scale 
(0-35) 
Dep: Includes depressed affect, positive affect, somatic 
complaint, interpersonal problem (CES-D) and depression, 
anxiety, insomnia, somatic complaint (HDRS) 
Dep: Median CES-D score: 
1.0; median HDRS score 
2.0 
 9 Bielak 2011 CES-D Dep:  Includes depressed affect, positive affect, somatic 
complaint, interpersonal problem 
Mean 50.1 
 32 Houde 2008 GDS Dep: Satisfaction with life, dropping activities and interests, 
feeling life is empty, being bored, not being hopeful about 
future, being bothered by thoughts, not being in good spirits, 
being afraid, feeling less happy, feeling helpless, being restless, 
not going out, worrying, memory problems, feeling 
downhearted and blue, feeling worthless, being less excited, 
having less energy, feeling upset, crying, difficulty 
concentrating, not enjoying getting up, avoiding social 
gathering, being less decisive, not having a clear mind 
Dep: 52 
 21 Dotson  2008 CES-D Dep:  Includes depressed affect, positive affect, somatic 
complaint, interpersonal problems 
NR 
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41 Mackin 2011 GDS Dep: Satisfaction with life, dropping activities and interests, 
feeling life is empty, being bored, not being hopeful about 
future, being bothered by thoughts, not being in good spirits, 
being afraid, feeling less happy, feeling helpless, being restless, 
not going out, worrying, memory problems, feeling 
downhearted and blue, feeling worthless, being less excited, 
having less energy, feeling upset, crying, difficulty 
concentrating, not enjoying getting up, avoiding social 
gathering, being less decisive, not having a clear mind 
Dep: 55 
 57 Wilson  2008 CES-D Dep:  Includes depressed affect, positive affect, somatic 
complaint, interpersonal problems 
Dep: 23.9 reporting 1, 9.7 
reporting 2, 6.1 reporting 
3 and 6.8 reporting 4 or 
more 
 Comparing cognitive groups     
 33 Janzing 2000 GMS AGECAT Dep: Subcase or depressive case Dep: Dementia - 
Depressive case: 12.2, 
subcase 20.4 
 10 Blansi 2005 NOSGER Dep: Mood NR 
 40 Li  2001 HDRS Dep: HDRS>7 and “motivationally related depressive 
symptoms", including loss of interest, fatigue, retardation, loss 
of energy and general somatic symptoms 
Dep: AD: 32.4; VAD: 29.7 
 11 Bunce 2012 Goldberg 
depression 
and anxiety 
scale 
Dep: 9 items including about energy, interest, confidence, 
hope, concentration, slowing, weight and waking Anx:  9 items 
including being on edge, worrying, being irritable, having 
difficulty relaxing, difficulty sleep, having headaches and 
physical symptoms 
NR 
 Dementia severity not reported      
 34 Jost  1996 Medical 
record review 
Dep: Depression, mood change, social withdrawal, suicidal 
ideation (reported as separate symptoms) Anx: Anxiety 
NR 
 42 Marin 1997 ADAS Dep: tearfulness, depressed mood Tearfulness - 
moderate/severe: 3,  very 
mild or greater: 20 
Depressed mood - 
moderate/severe: 5, very 
mild or greater: 42 
  
Psychotic symptoms 
  Author Year Instrument  Delusion / Hallucination / Misidentification  
        Definition Prevalence (%) 
Mild dementia (MMSE 21-26) 
22 
 
Eustace 2002 BEHAVE-AD Hal: Visual, auditory, olfactory and other hallucinations Del: 
Paranoid and delusional ideation (people are stealing things, 
one's house is not one's home, spouse or caregiver is 
imposter, abandonment, other)  
Del: 38 Hal: 0 
Moderate dementia (MMSE 15-20) 
39 Levy 1996 ADAS Psy: Hallucination (visual, auditory, tactile) and delusion (belief 
in ideas that are almost certainly not true) combined in 
psychosis subscale 
Psy: 11 
8 Berger 2005 BEHAVE-AD Psy symptoms cluster, Del: Paranoid and delusional ideation 
(people are stealing things, one's house is not one's home, 
spouse or caregiver is imposter, abandonment, other) Hal: 
Visual, auditory, olfactory and other hallucinations 
Median 0.0 
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50 Scarmeas
1a 
2002 CUSPAD Hal: Auditory, visual, tactile and olfactory illusions Del: 
General del (strange ideas or unusual beliefs), paranoid del 
(people are stealing things or unfaithful wife/husband or 
unfounded suspicions), abandonment del (accused caregiver 
of plotting to leave him/her), somatic del (false belief that the 
patient has cancer or other physical illness), misidentification 
(false belief that people are in the house when nobody is 
there, or that someone else is in the mirror, or that 
spouse/caregiver is an imposter, or that the patient's home is 
not home, or that the characters on TV are real) and a 
miscellaneous category. At least one of these.  
Del: 33.3 Hal: 11.5 
20 Devanan
d1a 
1997 CUSPAD Hal: Auditory, visual, tactile and olfactory Del: Paranoid del, 
misidentification (reported also separately), somatic and 
abandonment  
Del: 23.9 Hal: 8.1 
28 Holtzer1a 2003 CUSPAD Hal: Auditory, visual, tactile and olfactory Del: Paranoid del, 
misidentification (reported also separately), somatic and 
abandonment  
Del: 40 Hal: 8 
24 Garre-
Olmo 
2010 NPI-10 Hal: Including visions, voices, experiencing things that are not 
present Del: Beliefs that are not true, believing people are not 
who they say they are, believing their house is their home  
Del: 16.1 Hal: 5.5 
1 Aalten2 2005 NPI Hal: Including visions, voices, experiencing things that are not 
present Del: Beliefs that are not true, believing people are not 
who they say they are, believing their house is their home  
Del: 21.6 Hal: 9.5 
2 Aalten2 2005 NPI Psychosis cluster: Hallucinations and delusion (See Aalten2) See Aalten2 
25 Gillette-
Guyonnet 
2011 NPI Hal: Including visions, voices, experiencing things that are not 
present Del: Beliefs that are not true, believing people are not 
who they say they are, believing their house is their home  
Del: 9.3 Hal: 3.1 
49 Rosen  1991 DSMIII Hal: e.g. visual, auditory, olfactory Del: Various types e.g. 
paranoia, the belief that one’s spouse is an impostor  
Del: 34.4 Hal: 31.3 
48 Paulsen 2000 DIS  for the 
DSMIII 
Hal: e.g. visual, auditory, olfactory Del: Various types e.g. 
paranoia, the belief that one’s spouse is an impostor  
Psy: 23 
56 Wilkosz 2006 CERAD Hal: Sensory perceptions for which there was no basis in 
reality Del: A persistent false belief based on incorrect 
inference about external reality, resistant to persuasion or 
contrary evidence, and not attributable to social or cultural 
mores  
Del: 0 Hal: 0 (excluded 
those with symptoms at 
baseline) 
Moderately severe dementia (MMSE 10-14) 
19 Deudon 2009 CMAI, NPI and 
Observation 
Scale 
NPI Psychotic subgroup: Hal (Including visions, voices, 
experiencing things that are not present) and del (beliefs that 
are not true, believing people are not who they say they are, 
believing their house is their home) 
mean 6.14 (severity x 
frequency of 2 
symptoms) 
5 Ballard3 1997 Burn's 
symptom 
checklist 
Hal: If described by the patient or if clearly described to the 
informant by the patient Del: Beliefs that are false, firmly held 
and impervious to evidence to the contrary and that are not 
explained entirely by cognitive failure and that have been 
experienced at least twice, on occasions more than 1 week 
apart Mis: Included the categories of Capgras delusions, 
misidentification of house, misidentification of television, and 
misidentification of one’s mirror image. Symptoms also had to 
fulfil the definition for a delusion  
Psy: 65.0 
44 McShane
5 
1995 PBE Hal: Appears to have auditory or visual hallucinations NR (31.7 at some point 
during the study) 
30 Hope5  1999 PBE and Past 
behavioural 
history 
interview 
Hal: Appears to have auditory or visual hallucinations Del: 
Persecutory ideas: expressed ideas that people were trying to 
harm him/her, plotting against him/her or stealing or 
damaging his/her property  
NR 
45 McShane
5 
1998 PBE Hal: Appears to have auditory or visual hallucinations Del: 
Persecutory ideas: expressed ideas that people were trying to 
harm him/her, plotting against him/her or stealing or 
damaging his/her property  
Del: 11.6, Hal: 8.1 
26 Haupt4 1996 BEHAVE-AD Hal: Visual, auditory, olfactory and other hallucinations Del: 
Paranoid and delusional ideation (people are stealing things, 
Del: GDS 5: 48; GDS 6: 25; 
GDS 7: 14 Hal: GDS 5: 12; 
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one's house is not one's home, spouse or caregiver is 
imposter, abandonment, other)  
GDS 6: 25; GDS 7: 19 
27 Haupt4 2000 BEHAVE-AD Hal: Visual, auditory, olfactory and other hallucinations Del: 
Paranoid and delusional ideation (people are stealing things, 
one's house is not one's home, spouse or caregiver is 
imposter, abandonment, other)  
Del: 35 Hal: 18 
14 Chang 2004 SCID DSM IIIR Hal: Formed visual hallucinations, non-formed visual 
hallucinations, auditory hallucinations or other hallucinations 
(olfactory or tactile)Del: Thoughts or experiences of systematic 
persecution, non-systematic persecution, theft, infidelity or 
jealousy  
Del: 0 Hal: 0 Excluded 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 NPI nursing 
home version 
Hal: Including visions, voices, experiencing things that are not 
present Del: Beliefs that are not true, believing people are not 
who they say they are, believing their house is their home  
Del: 9.4 Hal: 3.4 
Dementia severity not reported  
15 Chen 1991 DSMIII-R  Psy: presence of persistent hallucinations, illusions or 
delusions 
25 
34 Jost  1996 Medical 
record review 
Hallucinations, paranoia, accusatory behaviour, and delusions 
(reported as separate symptoms) 
NR 
42 Marin 1997 ADAS Hal: visual, auditory, tactile hallucination Del: belief in ideas 
that are almost certainly not true 
Del: moderate/severe: 4. 
very mild or greater: 13  
Hal: moderate/severe: 1, 
very mild or greater: 7 
13 Caligiuri  2003 BEHAVE-AD Hal: Visual, auditory, olfactory and other hallucinations Del: 
Paranoid and delusional ideation (people are stealing things, 
one's house is not one's home, spouse or caregiver is 
imposter, abandonment, other)  
Del: 0 Hal: 0 (excluded 
those with symptoms at 
baseline) 
 
Hyperactivity symptoms 
  Author Year Instrument  Irritability / Agitation / Wandering   
        Definition Prevalence (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 BEHAVE-AD Irr: Verbal outbursts, physical threats and/or violence, other 
agitation Agi/Wan: activity disturbance, includes wandering 
and purposeless and inappropriate activities 
Irr: 42 Agi/Wan: 58 
Moderate dementia (MMSE 15-20) 
39 Levy 1996 ADAS Agi/Wan: Pacing and increased motor activity Agi/Wan: 25 
8 Berger 2005 BEHAVE-AD Behavioural disturbances cluster - aggressiveness, activity 
disturbances 
Median 1.0 
51 Scarmeas
1b 
2007 CUSPAD Agi/Wan: Agitation/restlessness Wan: Wandering away from 
home or from the caregiver Irr: Verbal outbursts, physical 
threats, violence 
NR 
50 Scarmeas
1a 
2002 CUSPAD Behavioural symptoms: wandering away from home, verbal 
outbursts, physical threats or violence, agitation or 
restlessness and sundowning 
Behavioural symptoms: 
56.3 
20 Devanan
d1a 
1997 CUSPAD Agi/Wan: Agitation/restlessness Irr: Verbal outbursts, physical 
threats, violence 
Agi/Wan: 38.7 Irr 
(physical aggression): 
6.4% 
28 Holtzer1a 2003 CUSPAD Agi/Wan: Agitation/restlessness Irr: Verbal outbursts, physical 
threats, violence 
Agi/Wan: 39 Irr: 6 
24 Garre-
Olmo 
2010 NPI-10 Agi/Wan: Includes pacing, repetitive behaviour Irr 
("irritability"): Includes getting irritated and easily disturbed; 
changeable moods, abnormally impatient; Irr ("agitation") 
refuses to cooperate or won’t let people help 
Agi/Wan: 18.9 Irr: 36.7; 
23 
1 Aalten2 2005 NPI Agi/Wan: Includes pacing, repetitive behaviour Irr 
("irritability"): Includes getting irritated and easily disturbed; 
changeable moods, abnormally impatient; Irr ("agitation") 
refuses to cooperate or won’t let people help 
Agi/Wan: 25.6 Irr: 23.6; 
18.6 
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2 Aalten2 2005 NPI Hyperactivity cluster: agitation, euphoria, irritability, 
disinhibition, aberrant motor behaviour. 
See 2 
25 Gillette-
Guyonnet 
2011 NPI Agi/Wan: Includes pacing, repetitive behaviour Irr 
("irritability"): Includes getting irritated and easily disturbed; 
changeable moods, abnormally impatient; Irr ("agitation") 
refuses to cooperate or won’t let people help 
Agi/Wan: 18.2 Irr: 20.6; 
21.3 
Moderately severe dementia (MMSE 10-14) 
19 Deudon 2009 CMAI, NPI 
and 
Observation 
Scale 
Agi: non-aggressive agitation (verbal and non-verbal) Irr: 
aggressive agitation (verbal and non-verbal); observational 
scale including screaming, hitting, tearing things, biting NPI 
Hyperactivity subgroup: Includes agi/wan (pacing, repetitive 
behaviour) and irr (anger, uncooperative) 
Agi: Physical non-
aggressive: mean 1.80; 
Verbal non-aggressive: 
mean 1.89  Irr: Physical 
aggressive: mean 1.28; 
Verbal aggressive mean 
2.32; Observation scale: 
mean 13.26 Hyperactivity 
subgroup: mean 35.68 
(severity x frequency of 5 
symptoms) 
23 Fauth 2006 Daily record 
of 
behaviour 
(DRB) 
Agi/Wan: Restless, pacing up and down Irr: Disruptive, 
physically aggressive behaviour, including hitting, kicking, 
biting, scratching, spitting, pushing, grabbing 
NR 
35 Keene5 1999 PBE Irr: Physical aggression (e.g. hitting, kicking, scratching, 
pushing or spitting in an aggressive manner), aggressive 
resistance (resisting help or being uncooperative), physical 
threats (e.g. shaking a fist), verbal aggression (spoken in an 
aggressive or angry way, e.g. angry or cross tone or voice 
raised in anger), refusing to speak (wilful or uncooperative), 
destructive behaviour (damaged objects in anger or 
deliberately), general irritability (bad mood or likely to become 
irritable at the least provocation), avoiding aggressive 
behaviour (carer avoided something that might have resulted 
in aggressive behaviour) 
Verbal aggression: 89; 
aggressive resistance: 71; 
physical aggression: 51; 
physical threats: 48; 
refusing to speak: 44; 
destructive behaviour: 
25; general irritability: 39; 
avoiding aggressive 
behaviour: 89 
31 Hope5  2001 PBE    Wan: Increased walking, walks distinctly more than normal; 
attempting to leave home, made attempts to leave the house 
that have been prevented; being brought back home, number 
of times being brought back home; trailing, tends to follow 
right behind carer for total of at least 30 minutes; aimless 
walking, walked about the house, garden or beyond without 
an obvious reason; pottering, tended to walk around the 
house trying to do household chores or potter around the 
garden trying to do odd jobs; inappropriate, walking around 
the house, garden or outside for a reason that seems odd to 
carer; excessive inappropriate, walked around the house, 
garden or outside for an appropriate reason but repeated this 
several times; night time walking, walked during the night, 
includes walking aimlessly, pottering and walking 
inappropriately or excessively 
Increased walking: 16; 
Attempting to leave 
home: 10; Being brought 
back home: 13; Trailing: 
21; Aimless walking: 21; 
Pottering: 19; 
Inappropriate or 
excessive appropriate: 10 
30 Hope5  1999 PBE and 
Past 
behavioural 
history 
interview 
Wan: Time spent walking; attempts to leave house; being 
brought back; trailing and checking; aimless walking Irr: 
Physical aggression towards others; aggressive resistance (i.e. 
resisting care during intimate care e.g. washing and dressing), 
verbal aggression  (i.e. spoke in an aggressive or angry way) 
NR 
45 McShane
5 
1998 PBE Irr: Verbal aggression  (i.e. spoke in an aggressive or angry 
way) 
Irr: 43 
4 Asada 1999 Troublesom
e behaviour 
scale (TBS) 
Irritability factor: false accusation, ill-natured denial and/or 
distortion, hiding and/or losing things, interfering with a happy 
home circle, being restless and/or noisy at night, physical 
and/or verbal aggression, repetition and/or clinging, pica. 
Hyperactivity factor: hiding and/or losing things, wandering, 
pica, rummaging, making the dwelling dirty, crying and/or 
screaming 
NR  
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43 McCarty 2000 Memory 
and 
Behaviour 
Problem 
Checklist-
Revised 
Emotional and impulsive behaviours cluster: confusing past 
and present, wandering/lost, restless/agitated, constantly 
talkative, waking people, sad/depressed, anxious/worried, 
angry, striking out, destroying property, dangerous behaviour 
mean 0.61 (0.57) of max 
3.00 
27 Haupt4 2000 BEHAVE-AD Irr: Verbal outbursts, physical threats and/or violence, other 
agitation Agi/Wan: activity disturbance, includes wandering 
and purposeless and inappropriate activities 
Agi: 87 Irr: 57/47 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 NPI nursing 
home 
version 
Agi/Wan: Includes pacing, repetitive behaviour Irr 
("irritability"): Includes getting irritated and easily disturbed; 
changeable moods, abnormally impatient; Irr ("agitation") 
refuses to cooperate or won’t let people help 
Agi/Wan: 23.1 Irr: 28.2; 
20.3 
12 Burgio 2007 Modified 
NHBPS and 
observation 
Irr: Including screaming, talking to self, moaning, cursing, 
complaining, repeated requests for attention, repetitive 
words, inappropriate disrobing, hitting, punching, spitting, 
pounding, banging objects, stomping feet, kicking, pushing, 
grabbing, scratching or throwing objects 
Total score Staff report: 
15.2 (of 56), observation: 
18.0 ( of 100) 
18 de Rooij 2012 QUALIDEM Agi: Restless behaviour NR 
Comparing cognitive groups 
10 Blansi 2005 NOSGER Disturbing behaviour NR 
Dementia severity not reported  
36 King-
Kallimani
s  
2010 Minimum 
dataset 
Wan: Locomotion with no discernible, rational purpose 14 
54 Volicer 2012 Minimum 
dataset 
Agi/Wan: Periods of restlessness, repetitive physical 
movements, wandering, socially inappropriate/disruptive 
behaviour 
75.6 
46; 
38 
Morgan; 
Kunik 
2012 CMAI Irr: intent to harm through spitting, verbal aggression, hitting, 
kicking, grabbing, pushing, throwing, biting, scratching, hurting 
self/others, tearing things/destroying property, making 
inappropriate verbal sexual advances or making inappropriate 
physical sexual advances 
Excluded at baseline 
17 Cohen-
Mansfield 
1998 CMAI-C Agi: Verbally non-aggressive behaviour; physically non 
aggressive behaviour Irr: Verbally aggressive behaviour and 
physically aggressive behaviour 
NR 
34 Jost  1996 Medical 
record 
review 
Irr: mild irr and severe irr (“aggression”) NR 
42 Marin 1997 ADAS Agi: tremors Agi/Wan: pacing, increased activity Irr: 
uncooperativeness cluster 
Agi: moderate/severe: 6, 
very mild or greater: 56 
Agi/Wan: pacing - 
moderate/severe: 8, very 
mild or greater: 18 
Increased activity - 
moderate/severe: 5, very 
mild or greater: 22 Irr: 
moderate/severe: 8, very 
mild or greater: 17 
 
Elation 
  Author Year Instrument  Elation   
        Definition Prevalence (%) 
Moderate dementia (MMSE 15-20) 
24 Garre-
Olmo 
2010 NPI-10 Too cheerful or too happy, abnormally good mood, finds 
humour where others do not 
9 
1 Aalten2 2005 NPI Too cheerful or too happy, abnormally good mood, finds 
humour where others do not 
3.5 
2 Aalten2 2005 NPI     
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25 Gillette-
Guyonnet 
2011 NPI Too cheerful or too happy, abnormally good mood, finds 
humour where others do not 
3.1 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 NPI nursing 
home 
version 
Too cheerful or too happy, abnormally good mood, finds 
humour where others do not 
4.3 
      
Sleep problems 
  Author Year Instrument  Sleep problems  
        Definition Prevalence (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 BEHAVE-AD Diurnal rhythm disturbances 21 
Moderate dementia (MMSE 15-20) 
8 Berger 2005 BEHAVE-AD Diurnal rhythm disturbance Median 0.0 
1 Aalten2 2005 NPI Difficulty sleeping, up at night, wander at night 13.1 
2 Aalten2 2005 NPI Difficulty sleeping, up at night, wander at night   
25 Gillette-
Guyonne
t 
2011 NPI Difficulty sleeping, up at night, wander at night 11.5 
Moderately severe dementia (MMSE 10-14) 
23 Fauth 2006 Daily record 
of 
behaviour 
(DRB) 
Woke caregiver up during the night NR 
30 Hope5  1999 PBE and 
Past 
behavioural 
history 
interview 
Disturbed diurnal rhythm: evidence of sever disruption of 
diurnal rhythm 
NR 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 NPI nursing 
home 
version 
Difficulty sleeping, up at night, wander at night 6 
Dementia severity not reported  
34 Jost  1996 Medical 
record 
review 
Diurnal change NR 
 
 
Reference numbers refer to the Online Reference List 
 
Papers from the same study groups: 
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General 
Hospital, USA 
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece) 
2 Maasbed study  
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol) 
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich) 
5 Hope et al. (Oxford) 
 
Apa=apathy 
Dep=depression 
Anx=anxiety 
Irr=irritability/aggression 
Agi=agitation 
Hal=hallucination 
Per=persecution 
Mis=misidentification 
Sle=sleep problems 
Wan=wandering 
Ela=elation 
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Fig. DS2 Persistence of BPSD reported in included studies 
 
Apathy 
 
Depression 
 
Anxiety 
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Fig. DS2 continued 
Irritability 
 
Agitation 
 
Hallucination 
 
 
 
20 
 
The figures show the percentage of participants in which the symptom persisted over the period indicated on the y-axis, 
and the 95% confidence interval. For each figure, a legend shows the author name, the duration of the total follow-up in 
months and the number of visits.  
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Table DS3 Persistence and remission of symptoms in those with symptoms at baseline 
Affective symptoms 
 
  Author Year Setting Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Depression / Anxiety / Apathy 
  
  
        
      
  Per measurement 
(%) 
Over total follow-
up (%) 
Fluctuating (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Transition probabilities (Markov 
model). 
Dep: 47 Anx: 52   
  
16 Clare 2012 DC 20 3 8-12 Random effects regression 
analysis. 
    Dep, anx: No significant 
change over time 
Moderate dementia (MMSE 15-20)  
39 Levy 1996 NR 12 5 3 No model; Present at all five visits 
when present at baseline. 
Dep: 49-59 37 
  
8 Berger 2005 DC 24 5 3-6 Total: each measurement time 
over 2 year period. Fluctuation: 
Present at 50% or more / less than 
50% of measurement time over 2 
yr. period.   
Dep: 16 Anx: 24 Dep: 38; 22 Anx: 31; 18 
20 Devanand1a 1997 DC 5 yrs. 
(mean 3 
yrs.) 
7 6 Per obs: Markov model; Total: 
present at any 4 visits; Fluctuating: 
present at 1 2 or 3 visits of any 4 
visits.  
Dep: 47 Dep: 8.3 Dep: 23.9; 17.2; 9.4 
24 Garre-Olmo 2010 DC 24 5 6 Linear and quadratic growth 
mixture models. 
    Factor score: Low and 
stable: 80.2%, High and 
decreasing: 9.0%, Low 
and increasing: 10.8% 
1 Aalten2 2005 DC 24 5 6 Present at any consecutive period 
of 6, 12, 18, 24 months. 
  
Dep: 21.2; 6.1; 
7.1; 2 Anx: 17.2; 
3; 2; 1 Apa: 9.1; 
20.2; 13.1; 12.1 
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2 Aalten2 2005 DC 24 5 6 Repeated measure analysis 
between symptoms and baseline 
and follow-up, adjusted for MMSE 
and duration of illness. 
  Mood/apa: 
F=14.2,  p<0.001 
(also associated 
with baseline NPI 
total, 
hyperactivity and 
psy) 
  
59 Zahodne 2013 DC 5.5 yrs. mean 
10.1 
6 Latent growth curve modelling.    No significant 
change - stable 
over time 
  
Moderately severe dementia (MMSE 10-14) 
  
23 Fauth 2006 NR 3 4 1 Latent growth curve modelling. A 
linear model of symptom change 
over time was compared to a 
model with a quadratic 
component and the fixed and 
random growth curve parameters 
of initial level, linear slope and 
quadratic slope were estimated. 
Log BPSD (frequency × duration 
+10) Covariates: MMSE score, use 
of neuroleptic medication, use of 
cholinesterase inhibitor, age, use 
of in-home respite care, 
relationship caregiver.   
Mood: Quadratic 
model. Significant 
intra-individual 
variability in rate 
of change 
  
6 Ballard3 1996 CLIN/DC 12 12 1 Percentage with minor dep at 
baseline that had 3 or more 
months dep; 6 or more months. 
  Dep: 28.6; 23.8 
  
30 Hope5  1999 CLIN  9 yrs. NR 4 Percentage with a single episode 
that persists until the last 
interview before death; 
Fluctuating: A single episode 
ending before death, more than 
one discrete episode, the 
behaviour may or may not persist 
until death.   
Dep: 37 Anx: 32 Dep: 47; 16 Anx: 57; 11 
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47 Neundorfer 2001 DC max: 
5yrs 
max:10 12 Hierarchical modelling or 
multilevel analysis. 
  
Dep: Changes 
over time within 
patients and 
differences 
between patients.    
27 Haupt4 2000 DC 24 3 12 % of those with symptoms at 
baseline with symptoms after 1 
and 2 years; Fluctuating: % with 
symptoms after 1 or 2 yrs.; % 
symptoms absent.   
Dep: 58.8 Anx: 
33.3 
Dep: 26.5; 14.7 Anx: 
28.6; 38.1 
Severe dementia (MMSE 0-9)  
55 Wetzels 2010 CH 24 5 6 No model. For each observation 0-1, 
1-2, 2-3, 3-4 months. 
Dep: 70.0, 37.5, 
12.4, 0.0 Anx: 39.8, 
42.9, 24.8, 31.4 
Apa: 54.8, 36.0, 
51.9, 39.4 
  
  
Normal cognitive function (MMSE 27+, no dementia)  
37 Kohler  2010 POP 6 3 3 Stability defined as a score within 
the upper quartile group on 2 
consecutive assessments: highly 
depressed at baseline only 
(fluctuating), highly depressed at 
follow-up only (fluctuating) and 
persistently highly depressed 
(total).   
Dep: 12 Dep: 8; 25 
41 Mackin 2011 VOL 3 yrs. 4 12 Proportion of individuals who 
remained stable, declined, 
improved, or fluctuated over 3 
years was calculated and compared 
between groups using Fisher’s 
exact test.   
Dep: 49 stable  Dep: 16 worsening, 8 
improved, 27 
fluctuations 
Comparing cognitive groups 
40 Li  2001 DC + 
VOL 
93.6 NR 3-12 Persistent: All HDRS scores during 
follow-up >7 Improved 
(fluctuating): All HDRS scores 
during follow-up <7 Fluctuating: 
HDRS scores at follow-up >7 or <7.   
Dep: AD 26.6; 
VAD 66.7; MCI 
60.0 
Dep: AD 66.7, 6.7; VAD 
22.2, 11.1; MCI 20.0, 
20.0 
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Psychotic symptoms 
  Author Year 
 
Setting Months 
follow-
up 
n BPSD 
measur
es 
Time 
between 
measures 
(months) 
Details Delusion / Hallucination / Misidentification 
  
  
        
      
  Per measurement 
(%) 
Over total follow-
up (%) 
Fluctuating (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Transition probabilities (Markov 
model). 
Del: 65 Hal: 25     
Moderate dementia (MMSE 15-20) 
39 Levy 1996 NR 12 5 3 No model; Present at all five visits 
when present at baseline. 
Psy: 68-82 Psy: 57 
  
8 Berger 2005 DC 24 5 3-6 Total: each measurement time 
over 2 year period; Fluctuation: 
Present at 50% or more / less 
than 50% of measurement time 
over 2 year period.   
Psy: 24 Psy: 20; 27 
20 Devanand1a 1997 DC 5 yrs. 
(mean 
3yrs) 
7 6 Per obs: Markov model; Total: 
present at any 4 visits; 
Fluctuating: present at 1; 2; 3 of 
any 4 visits.  
Del: 59 (includes 
mis) Hal: 52 
Del: 12.8 Hal: 5.6 Del: 20; 17.8; 18.9 Hal: 
18.9; 11.1; 4.4 
28 Holtzer1a 2003 DC 5 yrs. 11 6 Markov model. By mMMSE 39-
57, 33-38, 26-32, 14-25, 0-13. 
Del: 76, 75, 78, 82, 
64 Hal: 14, 42, 30, 
50, 43 
    
24 Garre-
Olmo 
2010 DC 24 5 6 Linear and quadratic growth 
mixture models. 
    Factor score: Moderate 
and stable: 6.9%, 
Fluctuating: 6.9%, Low 
and stable 86.2% 
1 Aalten2 2005 DC 24 5 6 Present at any consecutive 
period of 6, 12, 18, 24 months. 
  Del: 11.1; 3; 4; 4 
Hal: 5.1; 1; 1; 2 
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2 Aalten2 2005 DC 24 5 6 Repeated measure analysis 
between symptoms and baseline 
and follow-up, adjusted for 
MMSE and duration of illness. 
  Psy: F=28.3, 
p<0.001. Also 
associated with 
baseline NPI total 
and hyperactivity, 
not 
mood/apathy) 
  
49 Rosen  1991 DC 6 yrs. 7 1yr Percentage remission of those 
with at least one follow-up visit 
after onset symptom (n=6).  
    Psy: 33 
Moderately severe dementia (MMSE 10-14) 
19 Deudon 2009 CH 3 3 1 or 2 Mixed linear model with random 
effect. Covariates: age. 
  NPI psychosis 
factor: beta= 0.03 
(0.604) 
  
5 Ballard3 1997 CLIN/DC 12 12 1 Resolution of symptoms in those 
followed-up for a yr. 
    Psy: 53 Del: 73 Hal: 61 
Mis: 65 
44 McShane5 1995 CLIN 5 yrs. NR 4 Proportion of interviews were 
hallucinations were present. 
Hal: With cortical 
Lewy bodies: 0.44 
(SEM<0.15); 
without cortical 
Lewy bodies: 0.06 
(SEM 0.03) 
    
30 Hope5  1999 CLIN  9 yrs. NR 4 Percentage with a single episode 
that persists until the last 
interview before death; 
Fluctuating: A single episode 
ending before death; More than 
one discrete episode, the 
behaviour may or may not persist 
until death. 
  Del: 23 Hal: 42 Del: 68; 9 Hal: 42; 17 
27 Haupt4 2000 DC 24 3 12 % of those with symptoms at 
baseline with symptoms after 1 
and 2 years; Fluctuating: % with 
symptoms after 1 or 2 years; % 
symptoms absent. 
  Del: 0 Hal: 0 Del: 42.9; 57.1 Hal: 
72.7; 27.3 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
Del: 36.2, 28.3, 
12.5, 28.3 Hal: 50.0, 
25.0, 50.0, 50.0 
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Hyperactivity symptoms 
  
 
Author Year Setting Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Irritability / Agitation / Wandering 
  
  
        
      
  Per measurement 
(%) 
Over total follow-
up (%) 
Fluctuating (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Transition probabilities (Markov 
model). 
Irr: 70     
Moderate dementia (MMSE 15-20) 
39 Levy 1996 NR 12 5 3 No model; Present at all five visits 
when present at baseline. 
Agi/Wan: 65-67 Agi/Wan: 37 
 8 Berger 2005 DC 24 5 3-6 Total: each measurement time 
over 2 year period Fluctuation: 
Present at 50% or more / less 
than 50% of measurement time 
over 2 year period.   
Behavioural 
disturbances, 
aggressiveness, 
activity 
disturbances: 44 
Behavioural 
disturbances, 
aggressiveness, activity 
disturbances: 31; 16 
51 Scarmeas1b 2007 DC NR 14yrs max:25 Generalised estimating equation 
model. Disruptive behavioural 
symptoms.     
Symptoms increase by 
0.07 for every year of 
follow-up (p<0.001) 
20 Devanand1a 1997 DC 5 yrs. 
(mean 3 
yrs.) 
7 6 Per obs: Markov model; Total: 
present at any 4 visits; 
Fluctuating: present at 1; 2; 3 of 
any 4 visits.  
Agi/Wan: 74 Irr: 53 Agi/Wan: 32.8 Irr: 
2.8 
Agi/Wan: 14.4; 16.7; 
21.7 Irr: 14.4; 12.8; 8.9 
28 Holtzer1a 2003 DC 5 yrs. 11 6 Markov model. By mMMSE 39-
57, 33-38, 26-32, 14-25, 0-13. 
Agi/Wan: 54, 59, 
72, 81, 80 Irr: 27, 
20, 22, 59, 69 
    
24 Garre-Olmo 2010 DC 24 5 6 Linear and quadratic growth 
mixture models. 
    Factor score: Low and 
smooth increasing: 
66.6%, High and 
increasing: 4.3%, 
Moderate and stable: 
17.5%, Low and sharp 
increasing: 11.6% 
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1 Aalten2 2005 DC 24 5 6 Present at any consecutive 
period of 6, 12, 18, 24 months. 
  Agi/Wan: 21.2; 
9.1; 9.1; 6.1; Irr 
("irritability"): 
12.1; 11.1; 6.1; 1 
Irr ("agitation"): 
15.2; 6.1; 5.1; 0 
  
2 Aalten2 2005 DC 24 5 6 Repeated measure analysis 
between symptoms and baseline 
and follow-up, adjusted for 
MMSE and duration of illness. 
  Hyperactivity: 
F=4.8n p<0.05, 
Also associated 
with baseline NPI 
total, mood apathy 
and hyperactivity, 
but not psy 
  
Moderately severe dementia (MMSE 10-14) 
19 Deudon 2009 CH 3 3 1 or 2 Mixed linear model with random 
effect. Covariates: age. 
  Global CMAI: 
beta=0.02 (0.797) 
Physically non-
aggressive 
behaviour: beta=-
0.003 (0.368), 
verbally non-
aggressive 
behaviour: 
beta=0.001 (0.832) 
NPI hyperactivity 
factor: beta=0.35 
(0.091) Physically 
aggressive 
behaviour: 
beta=0.004 (0.11), 
verbally aggressive 
behaviour: beta=-
0.001 (0.776). 
Observation scale: 
beta=-0.16 (0.17) 
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23 Fauth 2006 NR 3 4 1 Latent growth curve modelling. A 
linear model of symptom change 
over time was compared to a 
model with a quadratic 
component and the fixed and 
random growth curve parameters 
of initial level, linear slope and 
quadratic slope were estimated. 
Log BPSD (frequency × duration 
+10) Covariates: MMSE score, 
use of neuroleptic medication, 
use of cholinesterase inhibitor, 
age, use of in-home respite care, 
relationship caregiver. 
  
Disruptive 
problems: 
Quadratic model. 
Disruptive 
behaviour: 
Significant intra-
individual 
variability in rate 
of change 
Restlessness: 
linear model. 
Significant 
variability of 
people's baseline 
scores.   
35 Keene5 1999 CLIN 10 yrs. 30 4 Persistence: Percentage with a 
single episode that persists until 
the last interview before death; 
Fluctuating: A single episode 
ending before death; More than 
one discrete episode, the 
behaviour may or may not persist 
until death. 
  Irr: verbal 
aggression: 54; 
aggressive 
resistance 60; 
physical 
aggression 51; 
physical threats 
29; refusal to 
speak 17; 
destructive 
behaviour 28; 
general irritability 
14; carer avoids 
aggression 44 
(Same population 
as Hope et al. ref 
43) 
Irr: verbal aggression: 
25; 21 aggressive 
resistance 18; 22 
physical aggression 33; 
16 physical threats 46; 
25 refusal to speak 72; 
11 destructive 
behaviour 68; 4 
general irritability 73; 
14 carer avoids 
aggression 40; 16 
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30 Hope5  1999 CLIN  9 yrs. NR 4 Percentage with a single episode 
that persists until the last 
interview before death; 
Fluctuating: A single episode 
ending before death; More than 
one discrete episode, the 
behaviour may or may not persist 
until death. 
  Wan: Trailing and 
checking: 33; 
aimless walking: 
35; being brought 
back 22; attempts 
to leave home 22; 
walking more 35; 
Irr: verbal 
aggression: 58; 
aggressive 
resistance 64; 
physical 
aggression 60 
Wan: Trailing and 
checking: 60; 7 aimless 
walking: 57; 9 being 
brought back 70; 9 
attempts to leave 
home 50; 28 walking 
more 50; 15 Irr: verbal 
aggression: 24; 18; 
aggressive resistance 
18; 18 physical 
aggression 30; 10 
27 Haupt4 2000 DC 24 3 12 % of those with symptoms at 
baseline with symptoms after 1 
and 2 years; Fluctuating: % with 
symptoms after 1 or 2 years; % 
symptoms absent. 
  Agi: 76.9; Irr: 46.4 Agi: 21.2; 1.9 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
Irr (“agitation”): 
51.4, 51.9, 37.6, 
56.1 Irr 
(“irritability”): 54.1, 
55.2, 62.4, 52.9 
Agi/Wan: 63.0, 
58.1, 41.9, 59.0  
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12 Burgio 2007 CH 18 4 6 Multilevel analysis. Restricted 
maximum likelihood estimation 
method with a specification of 
the unstructured covariance. 
Analysed linear and curvilinear 
time effects.  
  
Staff: Agitation 
changed little over 
the 18 month 
period; Obs: Both 
linear and 
quadratic effect 
were statistically 
significant (p<0.05) 
indicating that the 
trajectory of 
agitation had a 
decreasing trend 
linearly but the 
rate of decrease 
lessened over 
time.    
18 de Rooij 2012 CH 12 3 6 Changes across time within Dutch 
and Belgian traditional 
and small-scale settings. 
  Netherlands: 
coefficient -0.85; 
Belgium: -0.24 
  
Dementia severity not reported  
36 King-
Kallimanis  
2010 CH 4 yrs. 
(mean 
390/297 
days) 
mean: 4 3 Total: Wan at admission and for 
the duration of the study 
Fluctuating: Wan at admission 
and one change to a non-wan; 
Wan at admission and changed 
to wan and back to wan; Wan at 
admission and fluctuated 
multiple times. (% of all wan at 
baseline). 
Wan: 49 Wan: 43; 5; 3   
54 Volicer 2012 CH 15 4 3 Four groups: agi lower on first 
than last assessment (declined); 
higher agi score on first than last 
(improved), agi on both first and 
last (stable), not agi on first or 
last (no agi). In all second and 
third assessment intermediate 
between first and last. 
  Agi: increased 
19.6, decreased 
16.7, stable 46.2, 
no agi 17.3 
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17 Cohen-
Mansfield 
1998 CH 24 5 6 Repeated measures multivariate 
analyses of variances (MANOVA) 
CMAI syndrome scores: mean of 
behaviours comprising each type 
of agitation. 
Verbally non-
aggressive 
behaviour 
increased F=270, 
p=0.03; Physical 
non-aggressive 
behaviour NS 
Verbally aggressive 
behaviour 
increased over time 
F=3.83, p<0.01, 
Physically 
aggressive 
behaviour 
increased over time 
F=4.43, p<0.01     
 
Elation 
  
 
Author Year Setting Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Elation 
  
  
        
      
  Per measurement 
(%) 
Over total follow-up 
(%) 
Fluctuating (%) 
Moderate dementia (MMSE 15-20) 
1 Aalten2 2005 DC 24 5 6 Present at any consecutive 
period of 6, 12, 18, 24 months. 
  2, 0, 0, 0   
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
39.5, 17.6, 33.3, 
20.9 
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Sleep problems 
  Author Year Setting Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Sleep problems 
  
  
        
      
  Per measurement (%) Over total follow-up 
(%) 
Fluctuating (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Transition probabilities 
(Markov model). 
68     
Moderate dementia (MMSE 15-20) 
8 Berger 2005 DC 24 5 3-6 Total: each measurement time 
over 2 year period; Fluctuation: 
Present at 50% or more / less 
than 50% of measurement time 
over 2 year period.   
9 18; 29 
1 Aalten2 2005 DC 24 5 6 Present at any consecutive 
period of 6, 12, 18, 24 months. 
  10.1; 1; 1; 1 
  
Moderately severe dementia (MMSE 10-14) 
23 Fauth 2006 NR 3 4 1 Latent growth curve modelling. 
A linear model of symptom 
change over time was 
compared to a model with a 
quadratic component and the 
fixed and random growth curve 
parameters of initial level, 
linear slope and quadratic slope 
were estimated. Log BPSD 
(frequency × duration +10) 
Covariates: MMSE score, use of 
neuroleptic medication, use of 
cholinesterase inhibitor, age, 
use of in-home respite care, 
relationship caregiver.   
Linear model. 
Significant 
variability of 
people's baseline 
scores. Intra-
individual variability 
NS 
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30 Hope5  1999 CLIN  9 yrs. NR 4 Percentage with a single 
episode that persists until the 
last interview before death; 
Fluctuating: A single episode 
ending before death; More 
than one discrete episode, the 
behaviour may or may not 
persist until death. 
  23 68; 10 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each 
observation 0-1, 1-2, 2-3, 3-4.  
Sle: 56.7, 50.0, 0.0, 
20.9 
    
 
Total BPSD score 
  
 
Author Year Setting Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Total score 
 
Mild dementia (MMSE 21-26) 
16 Clare 2012 DC 20 3 8-12 Random effects regression analysis. Significant increase over time (lope 0.17, p<0.001), 
no significant change in severity 
52 Tschanz 2011 PB  Mean 3.8 
yrs., max 
12.9 yrs. 
NR NR Linear effects models, annual rate of change in 
NPI total. 
Increase of total NPI score over time: intercept: 2.5, 
time 3.1 (p=0.002) 
Moderate dementia (MMSE 15-20) 
2 Aalten2 2005 DC 24 5 6 Repeated measure analysis between symptoms 
and baseline and follow-up, adjusted for MMSE 
and duration of illness. 
NPI: F=16.5, p<0.001 Also associated with baseline 
mood/apathy, hyperactivity and psy 
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Moderately severe dementia (MMSE 10-14) 
23 Fauth 2006 NR 3 4 1 Latent growth curve modelling. A linear model of 
symptom change over time was compared to a 
model with a quadratic component and the fixed 
and random growth curve parameters of initial 
level, linear slope and quadratic slope were 
estimated. Log BPSD (frequency × duration +10) 
Covariates: MMSE score, use of neuroleptic 
medication, use of cholinesterase inhibitor, age, 
use of in-home respite care, relationship 
caregiver. 
No fixed or linear quadratic parameters were 
significant - on average no significant change over 
time for any domain, BPSD stable over 3 months 
 
Reference numbers refer to the Online Reference List 
 
Papers from the same study groups: 
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA 
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece) 
2 Maasbed study  
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol) 
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich) 
5 Hope et al. (Oxford) 
 
Settings  
DC=Dementia or memory clinic 
POP=Population-based 
CH=Care home 
CLIN=Referred by clinicians 
VOL=Volunteers 
NR=Not reported 
 
BPSD= behavioural and psychological symptoms of dementia 
Apa=apathy 
Dep=depression 
Anx=anxiety 
Irr=irritability/aggression 
Agi=agitation 
Hal=hallucination 
Per=persecution 
Mis=misidentification 
Sle=sleep problems 
Wan=wandering 
Ela=elation 
MMSE=mini mental state examination; mMMSE=modified mini mental state examination; SEM=standard error of the mean 
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Table DS4 Incidence and absence of symptoms in those without symptoms at baseline 
Affective symptoms 
 
  Author Year Setting  Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Depression / Anxiety 
/ Apathy 
    
                Per measurement (%) Over total follow-up 
(%) 
Absent (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Markov model. Transition 
probability for onset over 2 yr. 
period. 
Dep: 25 Anx: 28     
Moderate dementia (MMSE 15-20) 
39 Levy 1996 NR 12 5 3 Rate of new appearance of a 
symptom during the 
observation period in patients 
who had not reported the 
symptom at study onset. 
  Dep:35   
8 Berger 2005 DC 24 5 3-6 Absent at each measurement 
time over the 2 yr. period. 
    Dep: 24 Anx: 31 
50 Scarmeas1a 2002 NR 9.3 yrs. NR 6 Manifesting incident symptoms 
at any follow-up visit. 
Calculated from manifesting 
symptom at follow-up and no 
symptom at first visit.   
Dep: 73.5 
  
20 Devanand1a 1997 DC 5 yrs. 
(mean 3 
yrs.) 
7 6 Markov model. Absent: Of 
participants that completed 4 
consecutive periods of 6 
months: present at none of the 
4 visits. 
Dep: 14   Dep: 41.1 
1 Aalten2 2005 DC 24 5 6 Cumulative incidence: the 
proportion of patients who 
were symptom free at baseline 
but developed the specific 
symptom at next assessments.   
Dep: 33.4 Anx: 27.5 
Apa: 63.9 
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25 Gillette-
Guyonnet 
2011 DC max 48 mean 5.1 6 Incidence of NPI 4 or higher per 
100 person years and % events 
during 4 year follow-up in those 
without the symptom at 
baseline (between brackets).   
Dep: 16.5 (29.5) 
Anx: 19.6 (33.9) 
Apa: 41.7 (55.7) 
  
Moderately severe dementia (MMSE 10-14) 
6 Ballard3 1996 CLIN 12 12 1 Without major or minor 
depression at baseline interview   
Dep: 29.8 minor; 
10.6 major   
27 Haupt4 2000 DC 24 3 12 Absent at baseline and present 
after 1 or 2 years / 1 and 2 years 
(% without symptoms at 
baseline). Absent: absent at 
baseline and after 1 or 2 years 
(% without symptom at 
baseline). 
Dep: 26.9; 26.9 Anx: 
38.5; 7.7 
  
Dep: 50.0 Anx: 53.8 
14 Chang 2004 DC mean: 
51.9 
NR NR Symptoms developed during 
follow-up period, those with 
symptoms at baseline excluded.   
Dep: 12.5 
  
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
Dep: 8.4, 9.8, 3.0, 3.4 
Anx: 6.2, 9.7, 11.9, 8.5 
Apa: 13.7, 17.4, 27.2, 
18.8 
    
Normal cognitive function (MMSE 27+, no dementia) 
37 Kohler  2010 POP 6 3 3 Those who had symptoms at 
follow-up visits only Absent: 
never highly depressed. 
 
Dep: 25 Dep:55 
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Comparing cognitive groups 
 
40 Li  2001 DC + VOL 93.6 NR 3-12 Annual incidences of new-onset 
depressive symptoms among 
non-depressed subjects at 
baseline. No model. Calculated 
by dividing cumulative numbers 
of subjects showing new onset 
depressive symptoms (HDRS>7) 
by mean interval of follow-up 
years. 
Dep: AD - 15 per 100 
person years (8/26) 
MCI 11.7 (5/13) VAD 
26.8 (13/23)  
    
Dementia severity not reported  
34 Jost  1996 DC Retro-
spective 
using 
medical 
records 
Retro-
spective 
Retro-
spective 
Documentation of onset of 
symptoms in medical records. 
  Dep: 72   
 
Psychotic symptoms 
  
 
Author Year Setting  Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Delusion / Hallucination / Misidentification 
                Per measurement 
(%) 
Over total follow-up 
(%) 
Absent (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Markov model. Transition 
probability for onset over 2 yr. 
period. 
Del: 35 Hal: 7     
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Moderate dementia (MMSE 15-20) 
39 Levy 1996 NR 12 5 3 Rate of new appearance of a 
symptom during the observation 
period in patients who had not 
reported the symptom at study 
onset. 
  Del: 25   
8 Berger 2005 DC 24 5 3-6 Absent at each measurement 
time over the 2 year period. 
    Psy: 29 
50 Scarmeas1a 2002 NR 9.3 yrs. NR 6 Manifesting incident symptoms 
at any follow-up visit. Calculated 
from manifesting symptom at 
follow-up and no symptom at 
first visit.   
Del: 84.5 Hal: 45.5 
  
20 Devanand1a 1997 DC 5 yrs. 
(mean 3 
yrs.) 
7 6 Markov model. Absent: Of 
participants that completed 4 
consecutive periods of 6 months: 
present at none of the 4 visits. 
Del: 17 Hal: 9   Del: 30.6 Hal: 60 
28 Holtzer1a 2003 DC 5 yrs. 11 6 Markov model. By mMMSE 39-
57, 33-38, 26-32, 14-25, 0-13. 
Del: 76, 75, 78, 82, 
64 Hal: 14, 42, 30, 
50, 43 
    
1 Aalten2 2005 DC 24 5 6 Cumulative incidence: the 
proportion of patients who were 
symptom free at baseline but 
developed the specific symptom 
at next assessments.   
Del: 34 Hal: 20.5   
25 Gillette-
Guyonnet 
2011 DC max 48 mean 5.1 6 Incidence of NPI 4 or higher per 
100 person years and % events 
during 4 year follow-up in those 
without the  symptom at 
baseline (between brackets).   
Del: 8.2 (16.5) Hal: 
4.4 (9.4) 
  
49 Rosen  1991 DC 6 yrs. 7 1 yr. Emerging of psychosis by MMSE 
score. 
  
82.4 (n=14 of total 
n=32 of which n=15 
with symptoms 
during course) 
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48 Paulsen 2000 DC 4 yrs. 5 1 yr. The cumulative incidence for 
hallucinations or delusions in 
patients with a clinical diagnosis 
of probable AD   
20.1% at 1 year, 
36.1% at 2 years, 
49.5% at 3 years, 
and 51.3% at 4 years   
56 Wilkosz 2006 DC mean: 
25.8  
NR 1 yr. Only numbers and incidence rate 
given, I calculated percentages 
from this using n=288.   
Psy: 28.5 Del: 8.7 
Mis: 16.0 
  
Moderately severe dementia (MMSE 10-14) 
5 Ballard3 1997 DC 12 12 1 Percentage without symptoms at 
baseline that developed 
symptoms during follow-up. 
 
Psy: 47 Del: 30 Hal: 
20 Mis: 17 
  
27 Haupt4 2000 DC 24 3 12 Absent at baseline and present 
after 1 or 2 yrs. / 1 and 2 yrs. (% 
without symptoms at baseline). 
Absent: absent at baseline and 
after 1 or 2 years (% without 
symptom at baseline).   
Del: 29.7; 0 Hal: 
18.8; 2.1 
Del: 7 Hal: 79.2 
14 Chang 2004 DC mean: 
51.9 
NR NR Symptoms developed during 
follow-up period, those with 
symptoms at baseline excluded.   
Del: 32.1 Hal: 25 
  
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
Del: 2.9, 5.4, 5.5, 4.3 
Hal: 1.8, 2.7, 0.0, 5.1 
    
Dementia severity not reported  
15 Chen 1991 DC 5 yrs. 2 or more 6 Incidence during follow-up 
period.   
Psy: 29.6 
  
34 Jost  1996 DC Retro-
spective 
using 
medical 
records 
Retro-
spective 
Retro-
spective 
Documentation of onset of 
symptoms in medical records. 
  Psy: 45   
13 Caligiuri  2003 DC? NR 24 3 1 yrs. Incidence rate over 2 yrs. for new 
onset psychosis (those with 
symptoms at baseline excluded).   
Psy: 32.5 
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Hyperactivity symptoms 
  Author Year Setting  Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Irritability / Agitation / Wandering 
  
  
                Per measurement (%) Over total follow-up 
(%) 
Absent (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Markov model. Transition 
probability for onset over 2 yr. 
period. 
Irr: 38 
 
  
Moderate dementia (MMSE 15-20) 
39 Levy 1996 NR 12 5 3 Rate of new appearance of a 
symptom during the observation 
period in patients who had not 
reported the symptom at study 
onset. 
 Agi/Wan: 39   
8 Berger 2005 DC 24 5 3-6 Absent at each measurement 
time over the 2 year period. 
    9 (behavioural 
disturbance, 
aggressiveness, 
activity disturbance) 
50 Scarmeas1a 2002 NR 9.3 yrs. NR 6 Manifesting incident symptoms 
at any follow-up visit. Calculated 
from manifesting symptom at 
follow-up and no symptom at 
first visit.   
Behavioural 
symptoms 
(wandering and 
irritability): 94.7 
  
20 Devanand1a 1997 DC 5 yrs. 
(mean 3 
yrs.) 
7 6 Markov model. Absent: Of 
participants that completed 4 
consecutive periods of 6 months: 
symptom present at none of the 
4 visits. 
Agi/Wan: 31 Irr: 10   Agi/Wan: 14.4; Irr: 
61.1 
28 Holtzer1a 2003 DC 5 yrs. 11 6 Markov model. By mMMSE 39-
57, 33-38, 26-32, 14-25, 0-13. 
Agi/Wan: 54, 59, 72, 
81, 80 Irr: 27, 20, 22, 
59, 69     
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1 Aalten2 2005 DC 24 5 6 Cumulative incidence: the 
proportion of patients who were 
symptom free at baseline but 
developed the specific symptom 
at next assessments. 
  Agi/Wan: 48.7 Irr 
("irritability"): 33.5 
Irr ("agitation"): 
32.1 
  
25 Gillette-
Guyonnet 
2011 DC max 48 mean 5.1 6 Incidence of NPI 4 or higher per 
100 person years and % events 
during 4 year follow-up in those 
without the  symptom at baseline 
(between brackets). 
  Agi/Wan: 21.4 
(36.5) Irr 
("irritability"): 20.6 
(34.7) Irr 
("agitation"): 17.1 
(30.1) 
  
Moderately severe dementia (MMSE 10-14) 
45 McShane5 1998 CLIN  4 yrs. NR 4 Newly developed behaviours 
during 3 year period (association 
with symptoms in first year also 
reported). 
 
Irr: 31; Agi: 16.7 
  
27 Haupt4 2000 DC 24 3 12 Absent at baseline and present 
after 1 or 2 years / 1 and 2 years 
(% without symptoms at 
baseline). Absent: absent at 
baseline and after 1 or 2 years (% 
without symptom at baseline).   
Agi: 28.6; 71.4 Irr: 
31.3; 18.8 
Agi: 0 Irr: 50 
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
Irr (“agitation”): 9.5, 
20.6, 15.3, 23.1Irr 
(“agitation”): 17.2, 
18.2, 16.5, 23.1 
Agi/Wan: 15.6, 15.1, 
10.5, 18.8      
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Dementia severity not reported  
36 King-
Kallimanis  
2010 CH 4 yrs. 
(mean 
390/297 
days) 
mean:4 3 Of non-wan at admission, 
changed to wan and remained 
wan; Of non-wan at admission, 
changed to wan and back to non-
wan; Of non-wan at admission, 
changed to wan and fluctuated 
Absent: Of non-wan at admission, 
% that remained non wan for the 
duration of the study or until 
discharge.   
Wan: 3;2; 1  Wan: 94 
46; 38 Morgan; 
Kunik 
2012 DC 24 7 4 Incidence during follow-up period 
(incidence in first 5 months 
excluded in Morgan 2012, 
included in Kunik 2010).   
Agg: 38 (Morgan); 
41 (Kunik) 
  
34 Jost  1996 DC Retro-
spective 
using 
medical 
records 
Retro-
spective 
Retro-
spective 
Documentation of onset of 
symptoms in medical records. 
  Irr: 77 Wan: 43   
 
Elation 
  Author Year Setting  Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Elation 
  
                Per measurement (%) Over total follow-up 
(%) 
Absent (%) 
Moderate dementia (MMSE 15-20) 
1 Aalten2 2005 DC 24 5 6 Cumulative incidence: the 
proportion of patients who were 
symptom free at baseline but 
developed the specific symptom 
at the next assessments. 
  4.6   
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25 Gillette-
Guyonnet 
2011 DC max 48 mean 5.1 6 Incidence of NPI 4 or higher per 
100 person years and % events 
during 4 year follow-up in those 
without the  symptom at baseline 
(between brackets). 
  3.9 (8.2)   
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4 . 
3.6, 4.5, 2.7, 2.7 
 
  
 
Sleep problems 
  Author Year Setting  Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Sleep problems 
  
                Per measurement (%) Over total follow-up 
(%) 
Absent (%) 
Mild dementia (MMSE 21-26) 
22 Eustace 2002 DC 24 3 12 Markov model. Transition 
probability for onset over 2 year 
period. 
15 
    
Moderate dementia (MMSE 15-20) 
8 Berger 2005 DC 24 5 3-6 Absent at each measurement 
time over the 2 year period. 
   44 
1 Aalten2 2005 DC 24 5 6 Cumulative incidence: the 
proportion of patients who were 
symptom free at baseline but 
developed the specific symptom 
at next assessments.   
30.6   
25 Gillette-
Guyonnet 
2011 DC max 48 mean 5.1 6 Incidence of NPI 4 or higher per 
100 person years and % events 
during 4 year follow-up in those 
without the  symptom at baseline 
(between brackets).   
11.2 (21.5)   
Severe dementia (MMSE 0-9) 
55 Wetzels 2010 CH 24 5 6 No model. For each observation 
0-1, 1-2, 2-3, 3-4. 
1.8, 6.3, 4.7, 8.5 
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Dementia severity not reported  
34 Jost  1996 DC Retrosp
ective 
using 
medical 
records 
Retrospec
tive 
Retrospec
tive 
Documentation of onset of 
symptoms in medical records. 
  56%   
 
Reference numbers refer to the Online Reference List 
 
 
Papers from the same study groups: 
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA 
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece) 
2 Maasbed study  
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol) 
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich) 
5 Hope et al. (Oxford) 
 
Settings  
DC=Dementia or memory clinic 
POP=Population-based 
CH=Care home 
CLIN=Referred by clinicians 
VOL=Volunteers 
NR=Not reported 
 
BPSD= behavioural and psychological symptoms of dementia 
Apa=apathy 
Dep=depression 
Anx=anxiety 
Irr=irritability/aggression 
Agi=agitation 
Hal=hallucination 
Per=persecution 
Mis=misidentification 
Sle=sleep problems 
Wan=wandering 
Ela=elation 
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Fig. DS3 Incidence of BPS reported in included studies 
Apathy 
 
Depression 
 
Anxiety 
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Fig. DS3 continued 
Irritability 
 
Agitation 
 
Hallucination 
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Fig. DS3 continued 
Delusions 
 
 
Psychosis 
 
 
 
Sleep problems 
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Fig. DS3 continued 
Wandering 
 
 
 
Elation 
 
 
The figures show the percentage of participants in which new symptoms developed during the period indicated on the y-
axis, and the 95% confidence interval. For each figure, a legend shows the author name, the duration of the total follow-up 
in months and the number of visits.  
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Table DS5 Association BPSD and cognitive function 
Affective symptoms 
  Author Year Setting  Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details 
 
Covariates Score Depression / Anxiety / Apathy 
Moderate dementia (MMSE 15-20) 
29 Holtzer1b 2005 DC 14yrs 28 6 Time-dependent Cox analysis to 
evaluate if cognitive status 
predicted the first episode of dep 
during follow-up. General 
estimating equation with 
cognitive status, functional 
activity and disease duration as 
predictors, taking into account 
the multiple visits per patient as 
well as the likelihood that an 
individual's characteristics 
correlate with each other over 
time. Dichotomous depression 
outcome, also results for 
categorical and continuous 
outcomes in paper. 
Time, age, sex, 
education, cohort, 
antidepressant 
medication, 
Charlson 
comorbidity index. 
1 Depression dichotomous 
exclusive of physical 
symptoms, 2 frequency of 
depression exclusive of 
physical symptoms (5 level 
scale), 3 total depression 
scores inclusive of physical 
symptoms. 
Dep: Time dependent Cox analysis: mMMSE NS. GEE 
analysis with dichotomous outcome 1: mMMSE: 0.003 
(0.000-0.006) (p=0.03), Time: -0.0022 (-0.037-0.007) 
(p=0.004), BDRS 0.002 (0.001-0.002) (p<0.001); mMMSE NS 
using other 2 depression outcomes. 
2 Aalten2 2005 DC 24 5 6 Analyses of variance with 
repeated measures, overall 
between effects. MMSE at 
baseline and course of BPSD. 
Age, sex, SES, MMSE 
and GDS at baseline. 
Also symptoms at 
baseline and 
duration of illness. 
Three subsyndrome factors 
and NPI total score. 
Dep: NR (both MMSE and GDS) 
59 Zahodne 2013 DC 5.5yrs mean 10.1 6 Latent growth curve modelling. Cognitive decline 
and function. 
CUSPAD dep, continuous. Dep: higher level of dep was associated with worse initial 
functioning and faster subsequent cognitive and functional 
decline. 
Moderately severe dementia (MMSE 10-14) 
43 McCarty 2000 DC 24 3 1 Mean response of the items that 
loaded on each factor. Test-
retest correlations and mixed 
model analyses. 
By 4 severity levels 
based on initial 
MMSE score. 
BEHAVE-AD, total score 18 (6 
questions with maximum 
score 3). 
The patterns are similar for all factors (including 
Emotional/impulsive behaviours and apathy). Those with 
initial MMSE scores ranging from 11 to 30 (severity levels 1 
and 2) tended to show increased memory and behavioural 
problems across time, whereas those with initial MMSE 
scores ranging from 1 to 10 (severity 3) tended to show 
stable scores across time.  
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Normal cognitive function (MMSE 27+, no dementia) 
37 Kohler  2010 POP 6 3 3 Linear mixed-model analysis was 
used to measure the association 
between depressive symptom 
severity and cognitive decline 
from baseline to 3- and 6-year 
follow-up.  
Age, sex, education 
and baseline 
cognition scores. 
 . 
Stability of depression was 
defined as a score within the 
upper quartile group on 2 
consecutive assessments 
(baseline or follow-up (F1 or 
F2). This produced four 
groups: highly depressed at 
baseline only, highly 
depressed at follow-up only 
and persistently highly 
depressed.  
Participants who were persistently highly depressed over 
time showed a widespread pattern of decline, including 
memory (p<0.001), processing speed (p=0.002), and global 
cognition (p=0.0) when compared to participants who were 
never highly depressed. They also performed lower on 
baseline measures of processing speed (p=0.04) and 
attention and executive function (p<0.001).  
7 Becker  2009 POP 9yrs 9 12 Association between dep and 
cognitive function scores 1992-
1999 which was then examined 
as a predictor of the 
development of dementia 
between 2002-2007. Cox 
proportional hazard models. 
Age, ventricular 
grade. 
CESD score or correlation 
variable of CESD and 3MSE 
scores. 
No significant associations between non-dep/transiently 
dep/persistently dep in 1994-1998 and dementia after 
1998-1999 
53 Vinkers 2004 POP 4yrs 5 1 Separate linear mixed models. 
Additional annual increase of dep 
score per SD of cognitive function 
test score at baseline in those 
without dep at baseline 
(GDS15=<2) (p). 
Sex and educational 
level. 
Total GDS-15 score. Dep: Global cognitive function: -0.06 (0.17); Attention: 0.08 
(0.05); Processing speed:-0.03 (0.42); Immediate recall: -
0.17 (0.01); Delayed recall: -0.10 (0.02). 
3 Amieva 2008 POP 4yrs 7 12-36 Longitudinal analyses were done 
using a semiparametric extension 
of the mixed-effects linear 
model. The mean changes of the 
scores are assumed to be smooth 
curves, approximated by cubic 
splines.  
 
Total CES-D score. Dep: CES-D score over time before diagnosis of dementia / 
control: Slight increase in score with some minor 
fluctuation.  The score increased slightly but regularly in the 
pre-dementia group until the diagnosis and between 8 and 
7 years before diagnosis the curve of the predementia 
group became distinguishable from that of the control 
subjects.  
58 Wilson  2010 POP 8-9yrs mean: 3.6  36 Change in depression scores 
using GEE models. The models 
included a term for time in years 
since baseline, indicators for MCI 
and AD, interactions of indicators 
with time. Also reported for 
depressive domains.  
Age, sex, race, 
education. 
CES-D score ranging from 0-
10. Rate of 0.04 units per 
year equals 1 symptom per 
25 years. Also Hamilton 
Depression Rating Scale, 
ranging from 0-235. 
Dep: CES-D - Prediagnosis of AD: 0.04 (0.004); postdiagnosis 
of AD: -0.00 (0.913) Hamilton - scores did not change in any 
of the groups. 
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57 Wilson  2008 OTHER 13yrs mean:7.8 24 Generalised estimating equation 
models to analyse change in 
depressive symptoms before the 
diagnosis of AD (compared to 
those who never developed 
dementia) during the study 
period, with a logit-link function 
and a binomial error. Because 
preliminary analyses with 
quadratic terms for time showed 
no evidence of nonlinear change, 
all analyses are of linear change. 
Age, sex, education 
and interactions. 
Treating the number of 
reported symptoms as a 
proportion of the 10 possible 
symptoms. 
Dep: The rate of change in depressive symptoms in the 
incident AD subgroup did not differ from the rate in 
unaffected persons before the AD diagnosis (p=0.64) or 
after it (p=0.62). There was no systematic change in 
depressive symptoms in the unaffected subgroup or in the 
affected subgroup before (p=0.92) or after (p=0.16) the 
initial MCI diagnosis. 
  
32 Houde 2008 DC max:10 max:11 
(unsure) 
1 Cox proportional hazard of the 
association of symptoms and 
covariates with progression to 
dementia. 
Age, education, 
MMSE score, Apoe 
E4 status. 
GDS score. Dep: Persistent dep associated with progression to AD. MCI 
individuals who remained MCI: depression tended to 
improve in the first two years of follow-up. MCI who 
progressed to dementia: persistence of depression until the 
year prior to diagnosis as AD. After diagnosis, depression 
improved. 
21 Dotson  2008 VOL max 
26yrs 
NR 24 Linear mixed models using the 
PROC MIXED procedure in SAS. 
Yields information on the unique 
effects of each predictor, 
including both fixed and random 
effects. 
Baseline age, time 
interval and interval 
and interactions. 
Sex, self-reported 
race, educations 
and scores on the 
primary mental 
abilities vocabulary 
test. 
Continuous CES-D score. Dep: Higher average depressive symptoms were associated 
with poorer performance on TMT-A and TMT-B. Individuals 
with higher average CES-D scores showed greater 
longitudinal decline on CVLT-A, long delay free recall, 
BIMCS and MMSE. Some interaction effects. See table 5 
and figure 3. 
41 Mackin 2011 VOL 3yrs 4 12 Participants were classified ‘MCI 
converters’ if they were 
diagnosed with dementia within 
3 years of their 
baseline evaluation or ‘MCI 
cognitively stable’ if they did not 
progress to dementia during this 
interval. 
    Dep: no difference in stability between cognitively stable 
and those who progressed to dementia. 
9 Bielak 2011 POP 15yrs 5 2-6yrs Bivariate dual change score 
models. 
Age, education, 
baseline general 
cognitive ability and 
self-reported 
health.   
Dep: the data best fit the hypothesis that depressive 
symptoms predict subsequent change in perceptual speed. 
More depressive symptoms predicted subsequently 
stronger declines in perceptual speed over time lags of 1 
year. 
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Comparing cognitive groups 
33 Janzing 2000 CH 12 3 6 Logistic regression of dep and 
dementia. 
Age, sex, physical 
illness and somatic 
complaints. 
  Subjects with and without dementia had comparable 
baseline prevalences of depressive caseness (12.2% 
compared to 11.1, ns) and depression subcaseness (20.4% 
compared to 28.9%, ns). This remained stable during 12 
month follow-up.  
10 Blansi 2005 DC 3-4yrs 3-4 12 Linear and quadratic curves were 
fitted to repeated symptom and 
MMSE measurements for each 
patient. Linear (increasing) or 
quadratic (inverse U-shaped) 
course as a function of MMSE 
scores. 
Age, years of 
education and 
gender. 
  
Dep: Sign test for the analysis of a linear course (increasing) 
was significant p<0.01; Quadratic (inverse U shaped) not 
significant. 
11 Bunce 2012 PB max 12yrs max 4 4 yrs. Latent growth models estimating 
the intercept and slope of dep and 
anx symptoms. 
Cognitive measures. 
  
Dep: Higher initial scores of dep significantly associated 
with poorer initial performance on SLMT, verbal fluency 
and episodic memory, dep slope NS Anx: Higher initial 
scores of anx associated with poorer verbal fluency, anx 
slope NS. 
Dementia severity not reported 
17 Cohen- 
Mansfield 
1998 CH? 24 5 6 Repeated measures multivariate 
analyses of variances (MANOVA). 
  
CMAI syndrome scores: mean 
of behaviours comprising each 
type of agitation.   
42 Marin 1997 NR mean 37.1 mean:6.0 6 Matched sample t-tests.     Dep: NS for any year. 
 
Psychotic symptoms 
 
  Author Year Setting  Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Covariates Score Delusion / Hallucination / Misidentification 
Moderate dementia (MMSE 15-20) 
28 Holtzer1a 2003 DC 5yrs 11 6 GEE analyses to calculate the 
odds of having each of the 
psychopathological behaviours as 
a function of cognitive status in 
the entire sample with all 
available patient visits.  
Controlled for age, 
education and sex. 
  Del: mMMSE 39-57: ref; 33-38:1.4 (0.0314); 26-32: 2.3 
(<0.0001); 14-25: 2.4 (<0.0001); 0-13: 1.1 (0.8356) Hal: 
mMMSE 39-57: ref; 33-38:2.0 (0.0287); 26-32: 2.6 (0.0009); 
14-25: 3.3 (0.0001); 0-13: 2.6 (0.0059). 
2 Aalten2 2005 DC 24 5 6 Analyses of variance with 
repeated measures, overall 
between effects. MMSE at 
baseline and course of BPSD. 
Age, sex, social 
class, MMSE and 
GDS at baseline. 
Also symptoms at 
baseline and 
duration of illness. 
Three subsyndrome factors 
and NPI total score. 
MMSE at baseline related to higher level of psychosis at 
follow-up, F=3.5, p=0.034 - GDS NR. 
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49 Rosen  1991 DC 6yrs 7 1 yr. Cognitive decline during entire 
follow-up for those who 
developed symptoms compared 
to those that did not. 
    Patients who developed psychosis exhibited a more rapid 
rate of cognitive decline on average during the entire 
follow-up period than those who did not develop psychosis 
(p<0.03). 
Moderately severe dementia (MMSE 10-14) 
44 McShane5 1995 CLIN 4yrs NR 4 Analysis of covariance. Cortical Lewy 
bodies, visual 
problems, 
interaction term. 
Proportion of all interviews 
at which hallucinations had 
been rated positively. 
Hal: Cortical Lewy bodies associated with persistent 
hallucinations. Those who had ever had hallucinations 
(even if at only one interview) had significantly lower 
MMSE scores at their last interview (8.5 vs. 3.5, p=0.005); 
Cognitive decline did not have a significant independent 
effect on proportion of interviews with hallucinations, sum 
of squares 0.010, F=0.19, p=0.67. 
26 Haupt4 1996 DC 24 3 1 Association of psychotic 
symptoms with rate of cognitive 
decline, multiple stepwise 
regression. 
None BEHAVE-AD, total score 18 (6 
questions with maximum 
score 3). 
Del: 12 months change - CAMCOG: 0.03 (NS), MMSE: 0.02 
(NS), 24 months change - CAMCOG: 0.27 (significant), 
MMSE: 0.13 (NS) Hal: 12 months change - CAMCOG: 0.03 
(NS), MMSE: 0.04 (NS), 24 months change - CAMCOG: 0.01 
(NS), MMSE: 0.01 (NS) 
 
Hyperactivity symptoms 
  Author Year Setting  Months 
follow-up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Covariates Score Irritability / Agitation / Wandering 
Moderate dementia (MMSE 15-20) 
51 Scarmeas1b 2007 NR 14yrs max:25 6 Cox models predicting cognitive 
function by disruptive 
behavioural symptoms as time-
dependent covariates. Also 
sundowning, also unadjusted 
results reported. 
Controlled for 
cohort, recruitment 
centre, age, sex, 
education, baseline 
MMSE, baseline 
blessed dementia 
rating scale score, 
comorbidity index, 
use of 
cholinesterase 
inhibitors and use of 
neuroleptics. 
Disruptive behavioural 
symptoms. 
Agi: HR=1.64 (1.16-2.33) Wan: NS Irr: NS Total score: Sum 
(0-5): HR=1.21 (1.07-1.36); Any (0-1) HR=1.45 (1.03-2.03). 
28 Holtzer1a 2003 DC 5yrs 11 6 GEE analyses to calculate the 
odds of having each of the 
psychopathological behaviours as 
a function of cognitive status in 
the entire sample with all 
available patient visits.  
Controlled for age, 
education and sex. 
  
Wan: mMMSE 39-57: ref; 33-38:1.5 (0.0568); 26-32: 2.0 
(0.0064); 14-25: 3.3 (<0.0001); 0-13: 4.2 (<0.0001) Irr: 
mMMSE 39-57: ref; 33-38:3.5 (0.0016); 26-32: 3.1 (0.0001); 
14-25: 3.6 (<0.0001); 0-13: 9.0 (<0.0001). 
2 Aalten2 2005 DC 24 5 6 Analyses of variance with Age, sex, SES, MMSE Three subsyndrome factors Hyperactivity - Significant interaction between time and 
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repeated measures, overall 
between effects. MMSE at 
baseline and course of BPSD. 
and GDS at baseline. 
Also symptoms at 
baseline and 
duration of illness. 
and NPI total score. GDS, F=4.9, p=0.008 - MMSE NR. 
Moderately severe dementia (MMSE 10-14) 
31 Hope5  2001 CLIN Cog 9yrs mean:10.5 MMSE score at onset of 
behaviour and at death in 
participants included in the study 
for more than one year. 
Period with 
dementia. 
  Lower MMSE score and death associated with wan 
(p<0.05). Median MMSE scores at onset suggests 
progression from excessive but appropriate walking, 
attempts to leave the home and pottering, through to clear 
hyperactivity that becomes increasingly aimless and 
inappropriate. 
45 McShane5 1998 CLIN  4yrs NR 4 Relationship between symptoms 
and cognitive function in first 
year using Pearson X2 or 
student's t statistics as 
appropriate. 
    MMSE in year after entry lower in those with physical 
aggression than in those without (8.1 compared to 15.7, 
p<0.003) and in those with hyperactivity than in those 
without (9.2 compared to 16.0, p=0.001). 
4 Asada 1999 DC + 
VOL 
5yrs 6 1 Symptom change by baseline 
CDR stage: Repeated 
measurement analysis with the 
PROC MIXED program based 
only on the data for the subjects 
who completed all six 
assessments. Four candidate 
models were proposed: constant 
correlation, correlation declining 
exponentially with time, no 
mathematical pattern and no 
relation. Association symptom 
change and level of global 
impairment. 
  Behavioural factor score. See figure 1 and 2 Hyperactivity: CDR 2 and 3: slopes of the 
lines for hyperactivity showed a significant downward 
trend. Factor score reached its peak during the CDR 2 stage 
and followed a linear downward trend thereafter. 
Agitation: CDR 2 Significant downward trend, CDR 3 NS.  
Severe dementia (MMSE 0-9) 
12 Burgio 2007 CH 18 4 6 Examined cognitive status 
modelling time as a regression 
variable to compare cognitive 
status at specific times.     
Irr: Staff: no difference; Obs: profoundly impaired 
(MMSE=<7) changed little, moderately impaired (MMSE>7) 
symptoms improved slightly up to 12 months and 
worsened at the 18 month point.  
Comparing cognitive groups 
10 Blansi 2005 DC 3-4yrs 3-4 12 Linear and quadratic curves were 
fitted to repeated symptom and 
MMSE measurements for each 
patient. Linear (increasing) or 
quadratic (inverse U-shaped) 
course as a function of MMSE 
scores. 
Age, years of 
education and 
gender. 
  Agi: Disturbing behaviour: Linear and quadratic not 
significant. 
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Dementia severity not reported 
17 Cohen-
Mansfield 
1998 CH? 24 5 6 Repeated measures multivariate 
analyses of variances (MANOVA) 
  
 Agi: Physical non-aggressive behaviour: those with 
moderate or severe impairment increased twice as much as 
those who were cognitively intact at baseline, average 
increases were 0.30, 0.35 and 0.14. Verbally non-aggressive 
behaviour: all groups showed relatively constant levels over 
time, with the group with moderate levels of impairment 
manifesting consistently higher levels of agitation. Irr: Both 
types of aggressive behaviours show increases over time, 
not significantly influenced by cognitive function 
42 Marin 1997 NR mean 
37.1 
mean:6.0 6 Matched sample t-tests 
  
 Agi: NS for any year Pacing: Significant yearly change from 
baseline to year 1 (0.39 points, p=0.003) Irr: NS for any year 
 
Elation 
No results 
Sleep problems 
No results 
 
Total BPSD score 
  Author Year Setting  Months 
follow-
up 
n BPSD 
measures 
Time 
between 
measures 
(months) 
Details Covariates Score Total score 
Moderate dementia (MMSE 15-20) 
2 Aalten2 2005 DC 24 5 6 Analyses of variance with 
repeated measures. MMSE at 
baseline and course of BPSD 
Age, sex, SES, MMSE 
and GDS at baseline. 
Also symptoms at 
baseline and 
duration of illness 
Three subsyndrome factors 
and NPI total score 
Significant interaction between time and GDS score and 
the NPI total score, F=4.9, p=0.008. Severe dementia: 
scores decreased, mild dementia: scores increased - MMSE 
NR  
Dementia severity not reported 
42 Marin 1997 NR mean 
37.1 
mean:6.0 6 Matched sample t-tests   Total scores did not worsen significantly during any study 
year (year 1: p>-.05, year 2: p>0/1, year 3: p>0.1, year 4: 
p>0.1, year 5: p>0.1) 
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Reference numbers refer to the Online Reference List 
 
 
Papers from the same study groups: 
1a Predictors study 1: Columbia Medical Centre, John Hopkins University School of Medicine, Massachusetts General Hospital, USA 
1b Predictors study 2: 3 centres in USA (see 1a) and 2 centres in Europe (Paris and Greece) 
2 Maasbed study  
3 Ballard et al. (Psychiatry services in the West Midlands and a memory clinic in Bristol) 
4 Haupt et al. (Outpatient clinic at the institute of psychiatry of the Technical University in Munich) 
5 Hope et al. (Oxford) 
 
Settings  
DC=Dementia or memory clinic 
POP=Population-based 
CH=Care home 
CLIN=Referred by clinicians 
VOL=Volunteers 
NR=Not reported 
 
BPSD= behavioural and psychological symptoms of dementia 
Apa=apathy 
Dep=depression 
Anx=anxiety 
Irr=irritability/aggression 
Agi=agitation 
Hal=hallucination 
Per=persecution 
Mis=misidentification 
Sle=sleep problems 
Wan=wandering 
Ela=elatio
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Table DS6 Adherence to the PRISMA reporting guidelines 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title page 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration number.  
According to 
journal guidelines 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction 
section 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
Not relevant.  
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
Not available 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
Methods – 
eligibility criteria 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
Methods – search 
methods 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
eFigure1 
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Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
Not assessed 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
Not applicable 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
Results – 
characteristics – 
search results 
(text box) 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up 
period) and provide the citations.  
eTable 1 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Not assessed 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
No interventions. 
Results Figure 2 
and Figure 3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Not applicable 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
Methods – data 
synthesis 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
Methods – data 
synthesis 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
Methods – data 
synthesis 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
Not assessed 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods – data 
synthesis 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
Not applicable 
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Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Not assessed 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
Not applicable 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
Discussion 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete 
retrieval of identified research, reporting bias).  
Discussion 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
Discussion 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
Acknowlegements 
Abstract 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): 
e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org  
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